{
  "summary": {
    "total_tests": 204,
    "equivalent_results": 121,
    "different_results": 83,
    "high_significance_differences": 35,
    "medium_significance_differences": 48,
    "low_significance_differences": 0,
    "differences_by_focus": {
      "blast_thresholds": 12,
      "therapy_qualifiers": 1,
      "tp53_terminology": 6,
      "mds_blast_ranges": 18,
      "erythroid_handling": 8,
      "combination_scenarios": 2,
      "realistic_clinical_scenarios": 2,
      "age_dependent_differences": 10,
      "complex_cytogenetics": 2,
      "comutation_patterns": 4,
      "therapy_evolution": 2,
      "aml_vs_mds_borderline": 11,
      "disease_type_disagreement": 5
    },
    "differences_by_category": {
      "major_category_difference": 16,
      "mds_aml_hybrid_difference": 22,
      "diagnostic_uncertainty": 19,
      "category_difference": 26
    }
  },
  "test_results": [
    {
      "test_id": "test_000001",
      "input_data": {
        "blasts_percentage": 9,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA": true
        },
        "qualifiers": {},
        "expected_difference": true
      },
      "who_classification": "MDS with increased blasts 1 (WHO 2022)",
      "icc_classification": "MDS with excess blasts (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: CEBPA",
        "CEBPA found but blasts <20 => not AML by this route",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 9, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => CEBPA",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 9",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T19:49:19.477098"
    },
    {
      "test_id": "test_000002",
      "input_data": {
        "blasts_percentage": 9,
        "AML_defining_recurrent_genetic_abnormalities": {
          "bZIP": true
        },
        "qualifiers": {},
        "expected_difference": true
      },
      "who_classification": "MDS with increased blasts 1 (WHO 2022)",
      "icc_classification": "MDS with excess blasts (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: bZIP",
        "bZIP found but blasts <20 => not AML by this route",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 9, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => bZIP",
        "bZIP but blasts <10 => cannot label AML here",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 9",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T19:49:19.477155"
    },
    {
      "test_id": "test_000003",
      "input_data": {
        "blasts_percentage": 9,
        "AML_defining_recurrent_genetic_abnormalities": {
          "BCR::ABL1": true
        },
        "qualifiers": {},
        "expected_difference": true
      },
      "who_classification": "MDS with increased blasts 1 (WHO 2022)",
      "icc_classification": "MDS with excess blasts (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: BCR::ABL1",
        "BCR::ABL1 found but blasts <20 => not AML by this route",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 9, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => BCR::ABL1",
        "BCR::ABL1 but blasts <10 => cannot label AML here",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 9",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T19:49:19.477184"
    },
    {
      "test_id": "test_000004",
      "input_data": {
        "blasts_percentage": 9,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {},
        "expected_difference": false
      },
      "who_classification": "AML with NPM1 mutation (WHO 2022)",
      "icc_classification": "MDS with excess blasts (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with NPM1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 but blasts <10 => cannot label AML here",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 9",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "MDS",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "MDS with excess blasts",
        "who_category": "AML_GENETIC",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_category_difference",
        "significance": "high"
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T19:49:19.477217"
    },
    {
      "test_id": "test_000005",
      "input_data": {
        "blasts_percentage": 10,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA": true
        },
        "qualifiers": {},
        "expected_difference": true
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: CEBPA",
        "CEBPA found but blasts <20 => not AML by this route",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 10, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => CEBPA",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "mds_aml_hybrid_difference",
        "significance": "medium"
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T19:49:19.477255"
    },
    {
      "test_id": "test_000006",
      "input_data": {
        "blasts_percentage": 10,
        "AML_defining_recurrent_genetic_abnormalities": {
          "bZIP": true
        },
        "qualifiers": {},
        "expected_difference": true
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "AML with in-frame bZIP mutated CEBPA (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: bZIP",
        "bZIP found but blasts <20 => not AML by this route",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 10, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => bZIP",
        "bZIP => AML with in-frame bZIP mutated CEBPA",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with in-frame bZIP mutated CEBPA (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "AML with in-frame bZIP mutated CEBPA",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_GENETIC",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_category_difference",
        "significance": "high"
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T19:49:19.477291"
    },
    {
      "test_id": "test_000007",
      "input_data": {
        "blasts_percentage": 10,
        "AML_defining_recurrent_genetic_abnormalities": {
          "BCR::ABL1": true
        },
        "qualifiers": {},
        "expected_difference": true
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: BCR::ABL1",
        "BCR::ABL1 found but blasts <20 => not AML by this route",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 10, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => BCR::ABL1",
        "BCR::ABL1 => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_GENETIC",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_category_difference",
        "significance": "high"
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T19:49:19.477325"
    },
    {
      "test_id": "test_000008",
      "input_data": {
        "blasts_percentage": 10,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {},
        "expected_difference": false
      },
      "who_classification": "AML with NPM1 mutation (WHO 2022)",
      "icc_classification": "AML with mutated NPM1 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with NPM1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 => AML with mutated NPM1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated NPM1 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T19:49:19.477343"
    },
    {
      "test_id": "test_000009",
      "input_data": {
        "blasts_percentage": 15,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA": true
        },
        "qualifiers": {},
        "expected_difference": true
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: CEBPA",
        "CEBPA found but blasts <20 => not AML by this route",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => CEBPA",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "mds_aml_hybrid_difference",
        "significance": "medium"
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T19:49:19.477378"
    },
    {
      "test_id": "test_000010",
      "input_data": {
        "blasts_percentage": 15,
        "AML_defining_recurrent_genetic_abnormalities": {
          "bZIP": true
        },
        "qualifiers": {},
        "expected_difference": true
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "AML with in-frame bZIP mutated CEBPA (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: bZIP",
        "bZIP found but blasts <20 => not AML by this route",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => bZIP",
        "bZIP => AML with in-frame bZIP mutated CEBPA",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with in-frame bZIP mutated CEBPA (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "AML with in-frame bZIP mutated CEBPA",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_GENETIC",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_category_difference",
        "significance": "high"
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T19:49:19.477412"
    },
    {
      "test_id": "test_000011",
      "input_data": {
        "blasts_percentage": 15,
        "AML_defining_recurrent_genetic_abnormalities": {
          "BCR::ABL1": true
        },
        "qualifiers": {},
        "expected_difference": true
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: BCR::ABL1",
        "BCR::ABL1 found but blasts <20 => not AML by this route",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => BCR::ABL1",
        "BCR::ABL1 => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_GENETIC",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_category_difference",
        "significance": "high"
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T19:49:19.477446"
    },
    {
      "test_id": "test_000012",
      "input_data": {
        "blasts_percentage": 15,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {},
        "expected_difference": false
      },
      "who_classification": "AML with NPM1 mutation (WHO 2022)",
      "icc_classification": "AML with mutated NPM1 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with NPM1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 => AML with mutated NPM1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated NPM1 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T19:49:19.477464"
    },
    {
      "test_id": "test_000013",
      "input_data": {
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA": true
        },
        "qualifiers": {},
        "expected_difference": true
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: CEBPA",
        "CEBPA found but blasts <20 => not AML by this route",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 19, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => CEBPA",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "mds_aml_hybrid_difference",
        "significance": "medium"
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T19:49:19.477496"
    },
    {
      "test_id": "test_000014",
      "input_data": {
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {
          "bZIP": true
        },
        "qualifiers": {},
        "expected_difference": true
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "AML with in-frame bZIP mutated CEBPA (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: bZIP",
        "bZIP found but blasts <20 => not AML by this route",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 19, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => bZIP",
        "bZIP => AML with in-frame bZIP mutated CEBPA",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with in-frame bZIP mutated CEBPA (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "AML with in-frame bZIP mutated CEBPA",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_GENETIC",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_category_difference",
        "significance": "high"
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T19:49:19.477526"
    },
    {
      "test_id": "test_000015",
      "input_data": {
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {
          "BCR::ABL1": true
        },
        "qualifiers": {},
        "expected_difference": true
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: BCR::ABL1",
        "BCR::ABL1 found but blasts <20 => not AML by this route",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 19, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => BCR::ABL1",
        "BCR::ABL1 => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_GENETIC",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_category_difference",
        "significance": "high"
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T19:49:19.477556"
    },
    {
      "test_id": "test_000016",
      "input_data": {
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {},
        "expected_difference": false
      },
      "who_classification": "AML with NPM1 mutation (WHO 2022)",
      "icc_classification": "AML with mutated NPM1 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with NPM1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 => AML with mutated NPM1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated NPM1 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T19:49:19.477572"
    },
    {
      "test_id": "test_000017",
      "input_data": {
        "blasts_percentage": 20,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA": true
        },
        "qualifiers": {},
        "expected_difference": false
      },
      "who_classification": "AML with CEBPA mutation (WHO 2022)",
      "icc_classification": "AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: CEBPA",
        "CEBPA with blasts >=20 => AML with CEBPA mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with CEBPA mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => CEBPA",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "AML with CEBPA mutation",
        "icc_classification": "AML, NOS",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_NOS",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_category_difference",
        "significance": "high"
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T19:49:19.477602"
    },
    {
      "test_id": "test_000018",
      "input_data": {
        "blasts_percentage": 20,
        "AML_defining_recurrent_genetic_abnormalities": {
          "bZIP": true
        },
        "qualifiers": {},
        "expected_difference": false
      },
      "who_classification": "AML with CEBPA mutation (WHO 2022)",
      "icc_classification": "AML with in-frame bZIP mutated CEBPA (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: bZIP",
        "bZIP with blasts >=20 => AML with CEBPA mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with CEBPA mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => bZIP",
        "bZIP => AML with in-frame bZIP mutated CEBPA",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with in-frame bZIP mutated CEBPA (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with CEBPA mutation",
        "icc_classification": "AML with in-frame bZIP mutated CEBPA",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T19:49:19.477621"
    },
    {
      "test_id": "test_000019",
      "input_data": {
        "blasts_percentage": 20,
        "AML_defining_recurrent_genetic_abnormalities": {
          "BCR::ABL1": true
        },
        "qualifiers": {},
        "expected_difference": false
      },
      "who_classification": "AML with BCR::ABL1 fusion (WHO 2022)",
      "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: BCR::ABL1",
        "BCR::ABL1 with blasts >=20 => AML with BCR::ABL1 fusion",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with BCR::ABL1 fusion (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => BCR::ABL1",
        "BCR::ABL1 => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with BCR::ABL1 fusion",
        "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T19:49:19.477641"
    },
    {
      "test_id": "test_000020",
      "input_data": {
        "blasts_percentage": 20,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {},
        "expected_difference": false
      },
      "who_classification": "AML with NPM1 mutation (WHO 2022)",
      "icc_classification": "AML with mutated NPM1 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with NPM1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 => AML with mutated NPM1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated NPM1 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T19:49:19.477657"
    },
    {
      "test_id": "test_000021",
      "input_data": {
        "blasts_percentage": 25,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA": true
        },
        "qualifiers": {},
        "expected_difference": false
      },
      "who_classification": "AML with CEBPA mutation (WHO 2022)",
      "icc_classification": "AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: CEBPA",
        "CEBPA with blasts >=20 => AML with CEBPA mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with CEBPA mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => CEBPA",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "AML with CEBPA mutation",
        "icc_classification": "AML, NOS",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_NOS",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_category_difference",
        "significance": "high"
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T19:49:19.477685"
    },
    {
      "test_id": "test_000022",
      "input_data": {
        "blasts_percentage": 25,
        "AML_defining_recurrent_genetic_abnormalities": {
          "bZIP": true
        },
        "qualifiers": {},
        "expected_difference": false
      },
      "who_classification": "AML with CEBPA mutation (WHO 2022)",
      "icc_classification": "AML with in-frame bZIP mutated CEBPA (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: bZIP",
        "bZIP with blasts >=20 => AML with CEBPA mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with CEBPA mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => bZIP",
        "bZIP => AML with in-frame bZIP mutated CEBPA",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with in-frame bZIP mutated CEBPA (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with CEBPA mutation",
        "icc_classification": "AML with in-frame bZIP mutated CEBPA",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T19:49:19.477704"
    },
    {
      "test_id": "test_000023",
      "input_data": {
        "blasts_percentage": 25,
        "AML_defining_recurrent_genetic_abnormalities": {
          "BCR::ABL1": true
        },
        "qualifiers": {},
        "expected_difference": false
      },
      "who_classification": "AML with BCR::ABL1 fusion (WHO 2022)",
      "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: BCR::ABL1",
        "BCR::ABL1 with blasts >=20 => AML with BCR::ABL1 fusion",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with BCR::ABL1 fusion (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => BCR::ABL1",
        "BCR::ABL1 => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with BCR::ABL1 fusion",
        "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T19:49:19.477724"
    },
    {
      "test_id": "test_000024",
      "input_data": {
        "blasts_percentage": 25,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {},
        "expected_difference": false
      },
      "who_classification": "AML with NPM1 mutation (WHO 2022)",
      "icc_classification": "AML with mutated NPM1 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with NPM1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 => AML with mutated NPM1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated NPM1 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T19:49:19.477740"
    },
    {
      "test_id": "test_000025",
      "input_data": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Immune interventions"
        },
        "expected_difference": true
      },
      "who_classification": "AML with NPM1 mutation (WHO 2022)",
      "icc_classification": "AML with mutated NPM1, therapy related (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with NPM1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 => AML with mutated NPM1",
        "Detected ICC therapy => therapy related: Immune interventions",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => AML with mutated NPM1, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1, therapy related",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "therapy_qualifiers",
      "timestamp": "2025-06-06T19:49:19.477767"
    },
    {
      "test_id": "test_000026",
      "input_data": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "RUNX1::RUNX1T1": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Immune interventions"
        },
        "expected_difference": true
      },
      "who_classification": "AML with RUNX1::RUNX1T1 fusion (WHO 2022)",
      "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: RUNX1::RUNX1T1",
        "RUNX1::RUNX1T1 => AML with RUNX1::RUNX1T1 fusion",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with RUNX1::RUNX1T1 fusion (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => RUNX1::RUNX1T1",
        "RUNX1::RUNX1T1 => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1",
        "Detected ICC therapy => therapy related: Immune interventions",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with RUNX1::RUNX1T1 fusion",
        "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "therapy_qualifiers",
      "timestamp": "2025-06-06T19:49:19.477796"
    },
    {
      "test_id": "test_000027",
      "input_data": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "Immune interventions"
        },
        "expected_difference": true
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation (WHO 2022)",
      "icc_classification": "AML, NOS, therapy related (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "Detected ICC therapy => therapy related: Immune interventions",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => AML, NOS, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS, therapy related",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_THERAPY_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "diagnostic_uncertainty",
        "significance": "high"
      },
      "test_focus": "therapy_qualifiers",
      "timestamp": "2025-06-06T19:49:19.477833"
    },
    {
      "test_id": "test_000028",
      "input_data": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Ionising radiation"
        },
        "expected_difference": false
      },
      "who_classification": "AML with NPM1 mutation, previous cytotoxic therapy (WHO 2022)",
      "icc_classification": "AML with mutated NPM1, therapy related (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "Detected WHO therapy => previous cytotoxic therapy: Ionising radiation",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => AML with NPM1 mutation, previous cytotoxic therapy",
        "Final classification => AML with NPM1 mutation, previous cytotoxic therapy (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 => AML with mutated NPM1",
        "Detected ICC therapy => therapy related: Ionising radiation",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => AML with mutated NPM1, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation, previous cytotoxic therapy",
        "icc_classification": "AML with mutated NPM1, therapy related",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "therapy_qualifiers",
      "timestamp": "2025-06-06T19:49:19.477863"
    },
    {
      "test_id": "test_000029",
      "input_data": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "RUNX1::RUNX1T1": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Ionising radiation"
        },
        "expected_difference": false
      },
      "who_classification": "AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy (WHO 2022)",
      "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: RUNX1::RUNX1T1",
        "RUNX1::RUNX1T1 => AML with RUNX1::RUNX1T1 fusion",
        "No AML_differentiation provided.",
        "Detected WHO therapy => previous cytotoxic therapy: Ionising radiation",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy",
        "Final classification => AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => RUNX1::RUNX1T1",
        "RUNX1::RUNX1T1 => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1",
        "Detected ICC therapy => therapy related: Ionising radiation",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy",
        "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "therapy_qualifiers",
      "timestamp": "2025-06-06T19:49:19.477895"
    },
    {
      "test_id": "test_000030",
      "input_data": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "Ionising radiation"
        },
        "expected_difference": false
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy (WHO 2022)",
      "icc_classification": "AML, NOS, therapy related (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "Detected WHO therapy => previous cytotoxic therapy: Ionising radiation",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
        "Final classification => Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "Detected ICC therapy => therapy related: Ionising radiation",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => AML, NOS, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
        "icc_classification": "AML, NOS, therapy related",
        "who_category": "AML_THERAPY_RELATED",
        "icc_category": "AML_THERAPY_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "therapy_qualifiers",
      "timestamp": "2025-06-06T19:49:19.477929"
    },
    {
      "test_id": "test_000031",
      "input_data": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
        },
        "expected_difference": false
      },
      "who_classification": "AML with NPM1 mutation, previous cytotoxic therapy (WHO 2022)",
      "icc_classification": "AML with mutated NPM1, therapy related (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => AML with NPM1 mutation, previous cytotoxic therapy",
        "Final classification => AML with NPM1 mutation, previous cytotoxic therapy (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 => AML with mutated NPM1",
        "Detected ICC therapy => therapy related: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => AML with mutated NPM1, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation, previous cytotoxic therapy",
        "icc_classification": "AML with mutated NPM1, therapy related",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "therapy_qualifiers",
      "timestamp": "2025-06-06T19:49:19.477957"
    },
    {
      "test_id": "test_000032",
      "input_data": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "RUNX1::RUNX1T1": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
        },
        "expected_difference": false
      },
      "who_classification": "AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy (WHO 2022)",
      "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: RUNX1::RUNX1T1",
        "RUNX1::RUNX1T1 => AML with RUNX1::RUNX1T1 fusion",
        "No AML_differentiation provided.",
        "Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy",
        "Final classification => AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => RUNX1::RUNX1T1",
        "RUNX1::RUNX1T1 => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1",
        "Detected ICC therapy => therapy related: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy",
        "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "therapy_qualifiers",
      "timestamp": "2025-06-06T19:49:19.477989"
    },
    {
      "test_id": "test_000033",
      "input_data": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
        },
        "expected_difference": false
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy (WHO 2022)",
      "icc_classification": "AML, NOS, therapy related (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
        "Final classification => Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "Detected ICC therapy => therapy related: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => AML, NOS, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
        "icc_classification": "AML, NOS, therapy related",
        "who_category": "AML_THERAPY_RELATED",
        "icc_category": "AML_THERAPY_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "therapy_qualifiers",
      "timestamp": "2025-06-06T19:49:19.478024"
    },
    {
      "test_id": "test_000034",
      "input_data": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Any combination"
        },
        "expected_difference": false
      },
      "who_classification": "AML with NPM1 mutation, previous cytotoxic therapy (WHO 2022)",
      "icc_classification": "AML with mutated NPM1, therapy related (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "Detected WHO therapy => previous cytotoxic therapy: Any combination",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => AML with NPM1 mutation, previous cytotoxic therapy",
        "Final classification => AML with NPM1 mutation, previous cytotoxic therapy (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 => AML with mutated NPM1",
        "Detected ICC therapy => therapy related: Any combination",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => AML with mutated NPM1, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation, previous cytotoxic therapy",
        "icc_classification": "AML with mutated NPM1, therapy related",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "therapy_qualifiers",
      "timestamp": "2025-06-06T19:49:19.478052"
    },
    {
      "test_id": "test_000035",
      "input_data": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "RUNX1::RUNX1T1": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Any combination"
        },
        "expected_difference": false
      },
      "who_classification": "AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy (WHO 2022)",
      "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: RUNX1::RUNX1T1",
        "RUNX1::RUNX1T1 => AML with RUNX1::RUNX1T1 fusion",
        "No AML_differentiation provided.",
        "Detected WHO therapy => previous cytotoxic therapy: Any combination",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy",
        "Final classification => AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => RUNX1::RUNX1T1",
        "RUNX1::RUNX1T1 => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1",
        "Detected ICC therapy => therapy related: Any combination",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy",
        "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "therapy_qualifiers",
      "timestamp": "2025-06-06T19:49:19.478082"
    },
    {
      "test_id": "test_000036",
      "input_data": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "Any combination"
        },
        "expected_difference": false
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy (WHO 2022)",
      "icc_classification": "AML, NOS, therapy related (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "Detected WHO therapy => previous cytotoxic therapy: Any combination",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
        "Final classification => Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "Detected ICC therapy => therapy related: Any combination",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => AML, NOS, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
        "icc_classification": "AML, NOS, therapy related",
        "who_category": "AML_THERAPY_RELATED",
        "icc_category": "AML_THERAPY_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "therapy_qualifiers",
      "timestamp": "2025-06-06T19:49:19.478116"
    },
    {
      "test_id": "test_000037",
      "input_data": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "None"
        },
        "expected_difference": false
      },
      "who_classification": "AML with NPM1 mutation (WHO 2022)",
      "icc_classification": "AML with mutated NPM1 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with NPM1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 => AML with mutated NPM1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated NPM1 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "therapy_qualifiers",
      "timestamp": "2025-06-06T19:49:19.478133"
    },
    {
      "test_id": "test_000038",
      "input_data": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "RUNX1::RUNX1T1": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "None"
        },
        "expected_difference": false
      },
      "who_classification": "AML with RUNX1::RUNX1T1 fusion (WHO 2022)",
      "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: RUNX1::RUNX1T1",
        "RUNX1::RUNX1T1 => AML with RUNX1::RUNX1T1 fusion",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with RUNX1::RUNX1T1 fusion (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => RUNX1::RUNX1T1",
        "RUNX1::RUNX1T1 => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with RUNX1::RUNX1T1 fusion",
        "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "therapy_qualifiers",
      "timestamp": "2025-06-06T19:49:19.478152"
    },
    {
      "test_id": "test_000039",
      "input_data": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "None"
        },
        "expected_difference": false
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation (WHO 2022)",
      "icc_classification": "AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": true,
        "category_match": false,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "therapy_qualifiers",
      "timestamp": "2025-06-06T19:49:19.478172"
    },
    {
      "test_id": "test_000040",
      "input_data": {
        "blasts_percentage": 30.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {
          "predisposing_germline_variant": "Diamond-Blackfan anemia"
        },
        "expected_difference": true
      },
      "who_classification": "AML with NPM1 mutation (WHO 2022)",
      "icc_classification": "AML with mutated NPM1, in the setting of Diamond-Blackfan anemia (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 30.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "Final classification => AML with NPM1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 30.0",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 => AML with mutated NPM1",
        "Qualifier => in the setting of Diamond-Blackfan anemia",
        "Qualifiers appended => AML with mutated NPM1, in the setting of Diamond-Blackfan anemia (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1, in the setting of Diamond-Blackfan anemia",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "germline_qualifiers",
      "timestamp": "2025-06-06T19:49:19.478203"
    },
    {
      "test_id": "test_000041",
      "input_data": {
        "blasts_percentage": 30.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {
          "predisposing_germline_variant": "germline BLM mutation"
        },
        "expected_difference": true
      },
      "who_classification": "AML with NPM1 mutation, associated with germline BLM mutation (WHO 2022)",
      "icc_classification": "AML with mutated NPM1 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 30.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "Detected germline predisposition => associated with germline BLM mutation",
        "Classification with qualifiers => AML with NPM1 mutation, associated with germline BLM mutation",
        "Final classification => AML with NPM1 mutation, associated with germline BLM mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 30.0",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 => AML with mutated NPM1",
        "Final => AML with mutated NPM1 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation, associated with germline BLM mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "germline_qualifiers",
      "timestamp": "2025-06-06T19:49:19.478232"
    },
    {
      "test_id": "test_000042",
      "input_data": {
        "blasts_percentage": 30.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {
          "predisposing_germline_variant": "germline CEBPA mutation"
        },
        "expected_difference": false
      },
      "who_classification": "AML with NPM1 mutation, associated with germline CEBPA mutation (WHO 2022)",
      "icc_classification": "AML with mutated NPM1, in the setting of germline CEBPA mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 30.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "Detected germline predisposition => associated with germline CEBPA mutation",
        "Classification with qualifiers => AML with NPM1 mutation, associated with germline CEBPA mutation",
        "Final classification => AML with NPM1 mutation, associated with germline CEBPA mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 30.0",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 => AML with mutated NPM1",
        "Qualifier => in the setting of germline CEBPA mutation",
        "Qualifiers appended => AML with mutated NPM1, in the setting of germline CEBPA mutation (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation, associated with germline CEBPA mutation",
        "icc_classification": "AML with mutated NPM1, in the setting of germline CEBPA mutation",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "germline_qualifiers",
      "timestamp": "2025-06-06T19:49:19.478266"
    },
    {
      "test_id": "test_000043",
      "input_data": {
        "blasts_percentage": 30.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {
          "predisposing_germline_variant": "germline DDX41 mutation"
        },
        "expected_difference": false
      },
      "who_classification": "AML with NPM1 mutation, associated with germline DDX41 mutation (WHO 2022)",
      "icc_classification": "AML with mutated NPM1, in the setting of germline DDX41 mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 30.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "Detected germline predisposition => associated with germline DDX41 mutation",
        "Classification with qualifiers => AML with NPM1 mutation, associated with germline DDX41 mutation",
        "Final classification => AML with NPM1 mutation, associated with germline DDX41 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 30.0",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 => AML with mutated NPM1",
        "Qualifier => in the setting of germline DDX41 mutation",
        "Qualifiers appended => AML with mutated NPM1, in the setting of germline DDX41 mutation (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation, associated with germline DDX41 mutation",
        "icc_classification": "AML with mutated NPM1, in the setting of germline DDX41 mutation",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "germline_qualifiers",
      "timestamp": "2025-06-06T19:49:19.478298"
    },
    {
      "test_id": "test_000044",
      "input_data": {
        "blasts_percentage": 30.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {
          "predisposing_germline_variant": "Fanconi anaemia"
        },
        "expected_difference": false
      },
      "who_classification": "AML with NPM1 mutation, associated with Fanconi anaemia (WHO 2022)",
      "icc_classification": "AML with mutated NPM1, in the setting of Fanconi anaemia (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 30.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "Detected germline predisposition => associated with Fanconi anaemia",
        "Classification with qualifiers => AML with NPM1 mutation, associated with Fanconi anaemia",
        "Final classification => AML with NPM1 mutation, associated with Fanconi anaemia (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 30.0",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 => AML with mutated NPM1",
        "Qualifier => in the setting of Fanconi anaemia",
        "Qualifiers appended => AML with mutated NPM1, in the setting of Fanconi anaemia (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation, associated with Fanconi anaemia",
        "icc_classification": "AML with mutated NPM1, in the setting of Fanconi anaemia",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "germline_qualifiers",
      "timestamp": "2025-06-06T19:49:19.478330"
    },
    {
      "test_id": "test_000045",
      "input_data": {
        "blasts_percentage": 5,
        "Biallelic_TP53_mutation": {
          "2_x_TP53_mutations": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation (WHO 2022)",
      "icc_classification": "MDS with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
        "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with mutated TP53"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_TP53",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:49:19.478356"
    },
    {
      "test_id": "test_000046",
      "input_data": {
        "blasts_percentage": 10,
        "Biallelic_TP53_mutation": {
          "2_x_TP53_mutations": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation (WHO 2022)",
      "icc_classification": "MDS/AML with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
        "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_TP53",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:49:19.478389"
    },
    {
      "test_id": "test_000047",
      "input_data": {
        "blasts_percentage": 15,
        "Biallelic_TP53_mutation": {
          "2_x_TP53_mutations": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation (WHO 2022)",
      "icc_classification": "MDS/AML with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
        "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_TP53",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:49:19.478418"
    },
    {
      "test_id": "test_000048",
      "input_data": {
        "blasts_percentage": 20,
        "Biallelic_TP53_mutation": {
          "2_x_TP53_mutations": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation (WHO 2022)",
      "icc_classification": "AML with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML with mutated TP53",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "UNCLASSIFIABLE",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:49:19.478450"
    },
    {
      "test_id": "test_000049",
      "input_data": {
        "blasts_percentage": 25,
        "Biallelic_TP53_mutation": {
          "2_x_TP53_mutations": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation (WHO 2022)",
      "icc_classification": "AML with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML with mutated TP53",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "UNCLASSIFIABLE",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:49:19.478480"
    },
    {
      "test_id": "test_000050",
      "input_data": {
        "blasts_percentage": 5,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_del_17p": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation (WHO 2022)",
      "icc_classification": "MDS with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_del_17p': True}",
        "TP53 conditions: 2 mutations: False, with del17p: True, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: True, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with mutated TP53"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_TP53",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:49:19.478501"
    },
    {
      "test_id": "test_000051",
      "input_data": {
        "blasts_percentage": 10,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_del_17p": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation (WHO 2022)",
      "icc_classification": "MDS/AML with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_del_17p': True}",
        "TP53 conditions: 2 mutations: False, with del17p: True, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_TP53",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:49:19.478539"
    },
    {
      "test_id": "test_000052",
      "input_data": {
        "blasts_percentage": 15,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_del_17p": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation (WHO 2022)",
      "icc_classification": "MDS/AML with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_del_17p': True}",
        "TP53 conditions: 2 mutations: False, with del17p: True, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_TP53",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:49:19.478571"
    },
    {
      "test_id": "test_000053",
      "input_data": {
        "blasts_percentage": 20,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_del_17p": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation (WHO 2022)",
      "icc_classification": "AML with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML with mutated TP53",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "UNCLASSIFIABLE",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:49:19.478604"
    },
    {
      "test_id": "test_000054",
      "input_data": {
        "blasts_percentage": 25,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_del_17p": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation (WHO 2022)",
      "icc_classification": "AML with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML with mutated TP53",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "UNCLASSIFIABLE",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:49:19.478636"
    },
    {
      "test_id": "test_000055",
      "input_data": {
        "blasts_percentage": 5,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_LOH": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation (WHO 2022)",
      "icc_classification": "MDS with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_LOH': True}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: True, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: True, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with mutated TP53"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_TP53",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:49:19.478656"
    },
    {
      "test_id": "test_000056",
      "input_data": {
        "blasts_percentage": 10,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_LOH": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation (WHO 2022)",
      "icc_classification": "MDS/AML with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_LOH': True}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: True, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_TP53",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:49:19.478687"
    },
    {
      "test_id": "test_000057",
      "input_data": {
        "blasts_percentage": 15,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_LOH": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation (WHO 2022)",
      "icc_classification": "MDS/AML with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_LOH': True}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: True, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_TP53",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:49:19.478717"
    },
    {
      "test_id": "test_000058",
      "input_data": {
        "blasts_percentage": 20,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_LOH": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation (WHO 2022)",
      "icc_classification": "AML with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML with mutated TP53",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "UNCLASSIFIABLE",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:49:19.478748"
    },
    {
      "test_id": "test_000059",
      "input_data": {
        "blasts_percentage": 25,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_LOH": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation (WHO 2022)",
      "icc_classification": "AML with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML with mutated TP53",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "UNCLASSIFIABLE",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:49:19.478779"
    },
    {
      "test_id": "test_000060",
      "input_data": {
        "blasts_percentage": 5,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_50_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation (WHO 2022)",
      "icc_classification": "MDS with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with mutated TP53"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_TP53",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:49:19.478800"
    },
    {
      "test_id": "test_000061",
      "input_data": {
        "blasts_percentage": 10,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_50_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:49:19.478833"
    },
    {
      "test_id": "test_000062",
      "input_data": {
        "blasts_percentage": 15,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_50_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:49:19.478864"
    },
    {
      "test_id": "test_000063",
      "input_data": {
        "blasts_percentage": 20,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_50_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation (WHO 2022)",
      "icc_classification": "AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": true,
        "category_match": false,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:49:19.478884"
    },
    {
      "test_id": "test_000064",
      "input_data": {
        "blasts_percentage": 25,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_50_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation (WHO 2022)",
      "icc_classification": "AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": true,
        "category_match": false,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:49:19.478904"
    },
    {
      "test_id": "test_000065",
      "input_data": {
        "blasts_percentage": 5,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_10_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 1 (WHO 2022)",
      "icc_classification": "MDS with excess blasts (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_10_percent_vaf': True}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 5, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 5",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:49:19.478928"
    },
    {
      "test_id": "test_000066",
      "input_data": {
        "blasts_percentage": 5,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_10_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "Complex_karyotype": true
        },
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation (WHO 2022)",
      "icc_classification": "MDS with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_10_percent_vaf': True}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: True",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: True",
        "Biallelic TP53 detected => MDS with mutated TP53"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_TP53",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:49:19.478949"
    },
    {
      "test_id": "test_000067",
      "input_data": {
        "blasts_percentage": 10,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_10_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_10_percent_vaf': True}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 10, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_TP53",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:49:19.478984"
    },
    {
      "test_id": "test_000068",
      "input_data": {
        "blasts_percentage": 10,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_10_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "Complex_karyotype": true
        },
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation (WHO 2022)",
      "icc_classification": "MDS/AML with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_10_percent_vaf': True}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: True",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_TP53",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:49:19.479015"
    },
    {
      "test_id": "test_000069",
      "input_data": {
        "blasts_percentage": 15,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_10_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_10_percent_vaf': True}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_TP53",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:49:19.479045"
    },
    {
      "test_id": "test_000070",
      "input_data": {
        "blasts_percentage": 15,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_10_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "Complex_karyotype": true
        },
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation (WHO 2022)",
      "icc_classification": "MDS/AML with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_10_percent_vaf': True}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: True",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_TP53",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:49:19.479073"
    },
    {
      "test_id": "test_000071",
      "input_data": {
        "blasts_percentage": 20,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_10_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation (WHO 2022)",
      "icc_classification": "AML with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML with mutated TP53",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "UNCLASSIFIABLE",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:49:19.479103"
    },
    {
      "test_id": "test_000072",
      "input_data": {
        "blasts_percentage": 20,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_10_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "Complex_karyotype": true
        },
        "qualifiers": {}
      },
      "who_classification": "AML, myelodysplasia related (WHO 2022)",
      "icc_classification": "AML with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "MDS-related cytogenetic(s): Complex_karyotype => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "diagnostic_uncertainty",
        "significance": "high"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:49:19.479135"
    },
    {
      "test_id": "test_000073",
      "input_data": {
        "blasts_percentage": 25,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_10_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation (WHO 2022)",
      "icc_classification": "AML with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML with mutated TP53",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "UNCLASSIFIABLE",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:49:19.479166"
    },
    {
      "test_id": "test_000074",
      "input_data": {
        "blasts_percentage": 25,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_10_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "Complex_karyotype": true
        },
        "qualifiers": {}
      },
      "who_classification": "AML, myelodysplasia related (WHO 2022)",
      "icc_classification": "AML with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "MDS-related cytogenetic(s): Complex_karyotype => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "diagnostic_uncertainty",
        "significance": "high"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:49:19.479197"
    },
    {
      "test_id": "test_000075",
      "input_data": {
        "blasts_percentage": 4,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS, unclassifiable (WHO 2022)",
      "icc_classification": "MDS, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 4",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 4, fibrotic: False",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, unclassifiable (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 4",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 4",
        "number_of_dysplastic_lineages: None",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS, unclassifiable",
        "icc_classification": "MDS, NOS",
        "who_category": "MDS_NOS",
        "icc_category": "MDS_NOS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.479220"
    },
    {
      "test_id": "test_000076",
      "input_data": {
        "blasts_percentage": 4,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with low blasts and SF3B1 (WHO 2022)",
      "icc_classification": "MDS with mutated SF3B1 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 4",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 4, fibrotic: False",
        "SF3B1 mutation detected => MDS with low blasts and SF3B1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with low blasts and SF3B1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 4",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 4",
        "SF3B1 mutation detected => MDS with mutated SF3B1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with mutated SF3B1 (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with low blasts and SF3B1",
        "icc_classification": "MDS with mutated SF3B1",
        "who_category": "MDS_SF3B1",
        "icc_category": "MDS_SF3B1",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.479242"
    },
    {
      "test_id": "test_000077",
      "input_data": {
        "blasts_percentage": 4,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "del_5q": true
        },
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with low blasts and isolated 5q- (WHO 2022)",
      "icc_classification": "MDS with del(5q) (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 4",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 4, fibrotic: False",
        "del(5q) detected => MDS with low blasts and isolated 5q-",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with low blasts and isolated 5q- (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 4",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 4",
        "del(5q) detected => MDS with del(5q)",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with del(5q) (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with low blasts and isolated 5q-",
        "icc_classification": "MDS with del(5q)",
        "who_category": "MDS_5Q",
        "icc_category": "MDS_5Q",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.479264"
    },
    {
      "test_id": "test_000078",
      "input_data": {
        "blasts_percentage": 4,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "number_of_dysplastic_lineages": 2
      },
      "who_classification": "MDS with low blasts (WHO 2022)",
      "icc_classification": "MDS, NOS with multilineage dysplasia (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 4",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 4, fibrotic: False",
        "Multiple dysplastic lineages => MDS with low blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with low blasts (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 4",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 4",
        "number_of_dysplastic_lineages: 2",
        "Multilineage dysplasia => MDS, NOS with multilineage dysplasia",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, NOS with multilineage dysplasia (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with low blasts",
        "icc_classification": "MDS, NOS with multilineage dysplasia",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_DYSPLASIA",
        "are_equivalent": true,
        "category_match": false,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.479310"
    },
    {
      "test_id": "test_000079",
      "input_data": {
        "blasts_percentage": 4,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "fibrotic": true
      },
      "who_classification": "MDS, unclassifiable (WHO 2022)",
      "icc_classification": "MDS, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 4",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 4, fibrotic: True",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, unclassifiable (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 4",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 4",
        "number_of_dysplastic_lineages: None",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS, unclassifiable",
        "icc_classification": "MDS, NOS",
        "who_category": "MDS_NOS",
        "icc_category": "MDS_NOS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.479334"
    },
    {
      "test_id": "test_000080",
      "input_data": {
        "blasts_percentage": 4,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "hypoplasia": true
      },
      "who_classification": "MDS, hypoplastic (WHO 2022)",
      "icc_classification": "MDS, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 4",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 4, fibrotic: False",
        "Hypoplasia detected => MDS, hypoplastic",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, hypoplastic (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 4",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 4",
        "number_of_dysplastic_lineages: None",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS, hypoplastic",
        "icc_classification": "MDS, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "MDS_NOS",
        "are_equivalent": true,
        "category_match": false,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.479354"
    },
    {
      "test_id": "test_000081",
      "input_data": {
        "blasts_percentage": 5,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 1 (WHO 2022)",
      "icc_classification": "MDS with excess blasts (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 5, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 5",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.479376"
    },
    {
      "test_id": "test_000082",
      "input_data": {
        "blasts_percentage": 5,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 1 (WHO 2022)",
      "icc_classification": "MDS with excess blasts (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 5, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 5",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.479396"
    },
    {
      "test_id": "test_000083",
      "input_data": {
        "blasts_percentage": 5,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "del_5q": true
        },
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 1 (WHO 2022)",
      "icc_classification": "MDS with excess blasts (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 5, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 5",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.479417"
    },
    {
      "test_id": "test_000084",
      "input_data": {
        "blasts_percentage": 5,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "number_of_dysplastic_lineages": 2
      },
      "who_classification": "MDS with increased blasts 1 (WHO 2022)",
      "icc_classification": "MDS with excess blasts (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 5, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 5",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.479437"
    },
    {
      "test_id": "test_000085",
      "input_data": {
        "blasts_percentage": 5,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "fibrotic": true
      },
      "who_classification": "MDS, fibrotic (WHO 2022)",
      "icc_classification": "MDS with excess blasts (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 5, fibrotic: True",
        "5-9% blasts => MDS with increased blasts 1",
        "Blasts 5-19% with fibrotic marrow => MDS, fibrotic",
        "Current classification: MDS, fibrotic",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, fibrotic (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 5",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS, fibrotic",
        "icc_classification": "MDS with excess blasts",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": false,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.479457"
    },
    {
      "test_id": "test_000086",
      "input_data": {
        "blasts_percentage": 5,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "hypoplasia": true
      },
      "who_classification": "MDS with increased blasts 1 (WHO 2022)",
      "icc_classification": "MDS with excess blasts (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 5, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 5",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.479477"
    },
    {
      "test_id": "test_000087",
      "input_data": {
        "blasts_percentage": 8,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 1 (WHO 2022)",
      "icc_classification": "MDS with excess blasts (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 8, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 8",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.479497"
    },
    {
      "test_id": "test_000088",
      "input_data": {
        "blasts_percentage": 8,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 1 (WHO 2022)",
      "icc_classification": "MDS with excess blasts (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 8, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 8",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.479518"
    },
    {
      "test_id": "test_000089",
      "input_data": {
        "blasts_percentage": 8,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "del_5q": true
        },
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 1 (WHO 2022)",
      "icc_classification": "MDS with excess blasts (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 8, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 8",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.479538"
    },
    {
      "test_id": "test_000090",
      "input_data": {
        "blasts_percentage": 8,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "number_of_dysplastic_lineages": 2
      },
      "who_classification": "MDS with increased blasts 1 (WHO 2022)",
      "icc_classification": "MDS with excess blasts (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 8, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 8",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.479557"
    },
    {
      "test_id": "test_000091",
      "input_data": {
        "blasts_percentage": 8,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "fibrotic": true
      },
      "who_classification": "MDS, fibrotic (WHO 2022)",
      "icc_classification": "MDS with excess blasts (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 8, fibrotic: True",
        "5-9% blasts => MDS with increased blasts 1",
        "Blasts 5-19% with fibrotic marrow => MDS, fibrotic",
        "Current classification: MDS, fibrotic",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, fibrotic (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 8",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS, fibrotic",
        "icc_classification": "MDS with excess blasts",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": false,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.479577"
    },
    {
      "test_id": "test_000092",
      "input_data": {
        "blasts_percentage": 8,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "hypoplasia": true
      },
      "who_classification": "MDS with increased blasts 1 (WHO 2022)",
      "icc_classification": "MDS with excess blasts (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 8, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 8",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.479596"
    },
    {
      "test_id": "test_000093",
      "input_data": {
        "blasts_percentage": 9,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 1 (WHO 2022)",
      "icc_classification": "MDS with excess blasts (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 9, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 9",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.479616"
    },
    {
      "test_id": "test_000094",
      "input_data": {
        "blasts_percentage": 9,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 1 (WHO 2022)",
      "icc_classification": "MDS with excess blasts (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 9, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 9",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.479636"
    },
    {
      "test_id": "test_000095",
      "input_data": {
        "blasts_percentage": 9,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "del_5q": true
        },
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 1 (WHO 2022)",
      "icc_classification": "MDS with excess blasts (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 9, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 9",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.479656"
    },
    {
      "test_id": "test_000096",
      "input_data": {
        "blasts_percentage": 9,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "number_of_dysplastic_lineages": 2
      },
      "who_classification": "MDS with increased blasts 1 (WHO 2022)",
      "icc_classification": "MDS with excess blasts (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 9, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 9",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.479675"
    },
    {
      "test_id": "test_000097",
      "input_data": {
        "blasts_percentage": 9,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "fibrotic": true
      },
      "who_classification": "MDS, fibrotic (WHO 2022)",
      "icc_classification": "MDS with excess blasts (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 9, fibrotic: True",
        "5-9% blasts => MDS with increased blasts 1",
        "Blasts 5-19% with fibrotic marrow => MDS, fibrotic",
        "Current classification: MDS, fibrotic",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, fibrotic (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 9",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS, fibrotic",
        "icc_classification": "MDS with excess blasts",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": false,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.479694"
    },
    {
      "test_id": "test_000098",
      "input_data": {
        "blasts_percentage": 9,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "hypoplasia": true
      },
      "who_classification": "MDS with increased blasts 1 (WHO 2022)",
      "icc_classification": "MDS with excess blasts (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 9, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 9",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.479714"
    },
    {
      "test_id": "test_000099",
      "input_data": {
        "blasts_percentage": 10,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 10, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "mds_aml_hybrid_difference",
        "significance": "medium"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.479745"
    },
    {
      "test_id": "test_000100",
      "input_data": {
        "blasts_percentage": 10,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 10, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.479779"
    },
    {
      "test_id": "test_000101",
      "input_data": {
        "blasts_percentage": 10,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "del_5q": true
        },
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 10, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.479822"
    },
    {
      "test_id": "test_000102",
      "input_data": {
        "blasts_percentage": 10,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "number_of_dysplastic_lineages": 2
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 10, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "mds_aml_hybrid_difference",
        "significance": "medium"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.479854"
    },
    {
      "test_id": "test_000103",
      "input_data": {
        "blasts_percentage": 10,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "fibrotic": true
      },
      "who_classification": "MDS, fibrotic (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 10, fibrotic: True",
        "10-19% blasts => MDS with increased blasts 2",
        "Blasts 5-19% with fibrotic marrow => MDS, fibrotic",
        "Current classification: MDS, fibrotic",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, fibrotic (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS, fibrotic",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "diagnostic_uncertainty",
        "significance": "high"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.479885"
    },
    {
      "test_id": "test_000104",
      "input_data": {
        "blasts_percentage": 10,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "hypoplasia": true
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 10, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "mds_aml_hybrid_difference",
        "significance": "medium"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.479915"
    },
    {
      "test_id": "test_000105",
      "input_data": {
        "blasts_percentage": 15,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "mds_aml_hybrid_difference",
        "significance": "medium"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.479947"
    },
    {
      "test_id": "test_000106",
      "input_data": {
        "blasts_percentage": 15,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.479983"
    },
    {
      "test_id": "test_000107",
      "input_data": {
        "blasts_percentage": 15,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "del_5q": true
        },
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.480019"
    },
    {
      "test_id": "test_000108",
      "input_data": {
        "blasts_percentage": 15,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "number_of_dysplastic_lineages": 2
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "mds_aml_hybrid_difference",
        "significance": "medium"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.480049"
    },
    {
      "test_id": "test_000109",
      "input_data": {
        "blasts_percentage": 15,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "fibrotic": true
      },
      "who_classification": "MDS, fibrotic (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: True",
        "10-19% blasts => MDS with increased blasts 2",
        "Blasts 5-19% with fibrotic marrow => MDS, fibrotic",
        "Current classification: MDS, fibrotic",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, fibrotic (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS, fibrotic",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "diagnostic_uncertainty",
        "significance": "high"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.480079"
    },
    {
      "test_id": "test_000110",
      "input_data": {
        "blasts_percentage": 15,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "hypoplasia": true
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "mds_aml_hybrid_difference",
        "significance": "medium"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.480111"
    },
    {
      "test_id": "test_000111",
      "input_data": {
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 19, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "mds_aml_hybrid_difference",
        "significance": "medium"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.480141"
    },
    {
      "test_id": "test_000112",
      "input_data": {
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 19, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.480176"
    },
    {
      "test_id": "test_000113",
      "input_data": {
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "del_5q": true
        },
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 19, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.480211"
    },
    {
      "test_id": "test_000114",
      "input_data": {
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "number_of_dysplastic_lineages": 2
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 19, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "mds_aml_hybrid_difference",
        "significance": "medium"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.480244"
    },
    {
      "test_id": "test_000115",
      "input_data": {
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "fibrotic": true
      },
      "who_classification": "MDS, fibrotic (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 19, fibrotic: True",
        "10-19% blasts => MDS with increased blasts 2",
        "Blasts 5-19% with fibrotic marrow => MDS, fibrotic",
        "Current classification: MDS, fibrotic",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, fibrotic (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS, fibrotic",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "diagnostic_uncertainty",
        "significance": "high"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.480273"
    },
    {
      "test_id": "test_000116",
      "input_data": {
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "hypoplasia": true
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 19, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "mds_aml_hybrid_difference",
        "significance": "medium"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.480302"
    },
    {
      "test_id": "test_000117",
      "input_data": {
        "blasts_percentage": 20,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation (WHO 2022)",
      "icc_classification": "AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": true,
        "category_match": false,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.480321"
    },
    {
      "test_id": "test_000118",
      "input_data": {
        "blasts_percentage": 20,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "AML, myelodysplasia related (WHO 2022)",
      "icc_classification": "AML with myelodysplasia related gene mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "MDS-related mutation(s): SF3B1 => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.480343"
    },
    {
      "test_id": "test_000119",
      "input_data": {
        "blasts_percentage": 20,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "del_5q": true
        },
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "AML, myelodysplasia related (WHO 2022)",
      "icc_classification": "AML with myelodysplasia related cytogenetic abnormality (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "MDS-related cytogenetic(s): del_5q => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.480365"
    },
    {
      "test_id": "test_000120",
      "input_data": {
        "blasts_percentage": 20,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "number_of_dysplastic_lineages": 2
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation (WHO 2022)",
      "icc_classification": "AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": true,
        "category_match": false,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.480383"
    },
    {
      "test_id": "test_000121",
      "input_data": {
        "blasts_percentage": 20,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "fibrotic": true
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation (WHO 2022)",
      "icc_classification": "AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": true,
        "category_match": false,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.480402"
    },
    {
      "test_id": "test_000122",
      "input_data": {
        "blasts_percentage": 20,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "hypoplasia": true
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation (WHO 2022)",
      "icc_classification": "AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": true,
        "category_match": false,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:49:19.480420"
    },
    {
      "test_id": "test_000123",
      "input_data": {
        "blasts_percentage": 15,
        "AML_differentiation": "M6a",
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute Erythroid leukaemia (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "AML_differentiation: M6a",
        "Erythroid subtype => Acute Erythroid leukaemia",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute Erythroid leukaemia (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "Acute Erythroid leukaemia",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "diagnostic_uncertainty",
        "significance": "high"
      },
      "test_focus": "erythroid_handling",
      "timestamp": "2025-06-06T19:49:19.480448"
    },
    {
      "test_id": "test_000124",
      "input_data": {
        "blasts_percentage": 20,
        "AML_differentiation": "M6a",
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute Erythroid leukaemia (WHO 2022)",
      "icc_classification": "AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "AML_differentiation: M6a",
        "Erythroid subtype => Acute Erythroid leukaemia",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute Erythroid leukaemia (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "Acute Erythroid leukaemia",
        "icc_classification": "AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "diagnostic_uncertainty",
        "significance": "high"
      },
      "test_focus": "erythroid_handling",
      "timestamp": "2025-06-06T19:49:19.480475"
    },
    {
      "test_id": "test_000125",
      "input_data": {
        "blasts_percentage": 25,
        "AML_differentiation": "M6a",
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute Erythroid leukaemia (WHO 2022)",
      "icc_classification": "AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "AML_differentiation: M6a",
        "Erythroid subtype => Acute Erythroid leukaemia",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute Erythroid leukaemia (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "Acute Erythroid leukaemia",
        "icc_classification": "AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "diagnostic_uncertainty",
        "significance": "high"
      },
      "test_focus": "erythroid_handling",
      "timestamp": "2025-06-06T19:49:19.480501"
    },
    {
      "test_id": "test_000126",
      "input_data": {
        "blasts_percentage": 30,
        "AML_differentiation": "M6a",
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute Erythroid leukaemia (WHO 2022)",
      "icc_classification": "AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 30",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "AML_differentiation: M6a",
        "Erythroid subtype => Acute Erythroid leukaemia",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute Erythroid leukaemia (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 30",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "Acute Erythroid leukaemia",
        "icc_classification": "AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "diagnostic_uncertainty",
        "significance": "high"
      },
      "test_focus": "erythroid_handling",
      "timestamp": "2025-06-06T19:49:19.480527"
    },
    {
      "test_id": "test_000127",
      "input_data": {
        "blasts_percentage": 15,
        "AML_differentiation": "M6b",
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute Erythroid leukaemia (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "AML_differentiation: M6b",
        "Erythroid subtype => Acute Erythroid leukaemia",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute Erythroid leukaemia (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "Acute Erythroid leukaemia",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "diagnostic_uncertainty",
        "significance": "high"
      },
      "test_focus": "erythroid_handling",
      "timestamp": "2025-06-06T19:49:19.480552"
    },
    {
      "test_id": "test_000128",
      "input_data": {
        "blasts_percentage": 20,
        "AML_differentiation": "M6b",
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute Erythroid leukaemia (WHO 2022)",
      "icc_classification": "AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "AML_differentiation: M6b",
        "Erythroid subtype => Acute Erythroid leukaemia",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute Erythroid leukaemia (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "Acute Erythroid leukaemia",
        "icc_classification": "AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "diagnostic_uncertainty",
        "significance": "high"
      },
      "test_focus": "erythroid_handling",
      "timestamp": "2025-06-06T19:49:19.480578"
    },
    {
      "test_id": "test_000129",
      "input_data": {
        "blasts_percentage": 25,
        "AML_differentiation": "M6b",
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute Erythroid leukaemia (WHO 2022)",
      "icc_classification": "AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "AML_differentiation: M6b",
        "Erythroid subtype => Acute Erythroid leukaemia",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute Erythroid leukaemia (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "Acute Erythroid leukaemia",
        "icc_classification": "AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "diagnostic_uncertainty",
        "significance": "high"
      },
      "test_focus": "erythroid_handling",
      "timestamp": "2025-06-06T19:49:19.480603"
    },
    {
      "test_id": "test_000130",
      "input_data": {
        "blasts_percentage": 30,
        "AML_differentiation": "M6b",
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute Erythroid leukaemia (WHO 2022)",
      "icc_classification": "AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 30",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "AML_differentiation: M6b",
        "Erythroid subtype => Acute Erythroid leukaemia",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute Erythroid leukaemia (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 30",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "Acute Erythroid leukaemia",
        "icc_classification": "AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "diagnostic_uncertainty",
        "significance": "high"
      },
      "test_focus": "erythroid_handling",
      "timestamp": "2025-06-06T19:49:19.480629"
    },
    {
      "test_id": "test_000131",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "Immune interventions"
        },
        "blasts_percentage": 15
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML, NOS, therapy related (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: CEBPA",
        "CEBPA found but blasts <20 => not AML by this route",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => CEBPA",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "Detected ICC therapy => therapy related: Immune interventions",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => MDS/AML, NOS, therapy related (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS, therapy related",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_THERAPY_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "combination_scenarios",
      "timestamp": "2025-06-06T19:49:19.480666"
    },
    {
      "test_id": "test_000132",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {
          "2_x_TP53_mutations": true
        },
        "qualifiers": {
          "predisposing_germline_variant": "Diamond-Blackfan anemia"
        },
        "blasts_percentage": 20
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation (WHO 2022)",
      "icc_classification": "AML with mutated TP53, in the setting of Diamond-Blackfan anemia (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts >=20 => remain AML",
        "Qualifier => in the setting of Diamond-Blackfan anemia",
        "Qualifiers appended => AML with mutated TP53, in the setting of Diamond-Blackfan anemia (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML with mutated TP53, in the setting of Diamond-Blackfan anemia",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "UNCLASSIFIABLE",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "combination_scenarios",
      "timestamp": "2025-06-06T19:49:19.480708"
    },
    {
      "test_id": "test_000133",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_del_17p": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Immune interventions"
        },
        "blasts_percentage": 12
      },
      "who_classification": "MDS with biallelic TP53 inactivation (WHO 2022)",
      "icc_classification": "MDS/AML with mutated TP53, therapy related (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 12",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_del_17p': True}",
        "TP53 conditions: 2 mutations: False, with del17p: True, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 12",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
        "Detected ICC therapy => therapy related: Immune interventions",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => MDS/AML with mutated TP53, therapy related (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53, therapy related",
        "who_category": "MDS_TP53",
        "icc_category": "AML_THERAPY_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "combination_scenarios",
      "timestamp": "2025-06-06T19:49:19.480743"
    },
    {
      "test_id": "test_000134",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "ASXL1": true,
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "blasts_percentage": 25,
        "AML_differentiation": "M6a"
      },
      "who_classification": "AML, myelodysplasia related (WHO 2022)",
      "icc_classification": "AML with myelodysplasia related gene mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "MDS-related mutation(s): ASXL1, SF3B1 => AML, myelodysplasia related",
        "AML_differentiation: M6a",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "combination_scenarios",
      "timestamp": "2025-06-06T19:49:19.480764"
    },
    {
      "test_id": "test_000135",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "blasts_percentage": 0
      },
      "who_classification": "MDS, unclassifiable (WHO 2022)",
      "icc_classification": "MDS, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 0, fibrotic: False",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, unclassifiable (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 0",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 0",
        "number_of_dysplastic_lineages: None",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS, unclassifiable",
        "icc_classification": "MDS, NOS",
        "who_category": "MDS_NOS",
        "icc_category": "MDS_NOS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "edge_cases",
      "timestamp": "2025-06-06T19:49:19.480785"
    },
    {
      "test_id": "test_000136",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "blasts_percentage": 100
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation (WHO 2022)",
      "icc_classification": "AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 100",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 100",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": true,
        "category_match": false,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "edge_cases",
      "timestamp": "2025-06-06T19:49:19.480804"
    },
    {
      "test_id": "test_000137",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true,
          "RUNX1::RUNX1T1": true,
          "CBFB::MYH11": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "blasts_percentage": 25
      },
      "who_classification": "AML with NPM1 mutation (WHO 2022)",
      "icc_classification": "AML with mutated NPM1 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1, RUNX1::RUNX1T1, CBFB::MYH11",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with NPM1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1, RUNX1::RUNX1T1, CBFB::MYH11",
        "NPM1 => AML with mutated NPM1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated NPM1 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "edge_cases",
      "timestamp": "2025-06-06T19:49:19.480822"
    },
    {
      "test_id": "test_000138",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "ASXL1": true,
          "RUNX1": true,
          "SF3B1": true,
          "SRSF2": true,
          "U2AF1": true,
          "EZH2": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "blasts_percentage": 8
      },
      "who_classification": "MDS with increased blasts 1 (WHO 2022)",
      "icc_classification": "MDS with excess blasts (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 8, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 8",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "edge_cases",
      "timestamp": "2025-06-06T19:49:19.480843"
    },
    {
      "test_id": "test_000139",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {
          "2_x_TP53_mutations": true,
          "1_x_TP53_mutation_del_17p": true,
          "1_x_TP53_mutation_LOH": true,
          "1_x_TP53_mutation_50_percent_vaf": true,
          "1_x_TP53_mutation_10_percent_vaf": true
        },
        "qualifiers": {},
        "blasts_percentage": 15
      },
      "who_classification": "MDS with biallelic TP53 inactivation (WHO 2022)",
      "icc_classification": "MDS/AML with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'2_x_TP53_mutations': True, '1_x_TP53_mutation_del_17p': True, '1_x_TP53_mutation_LOH': True, '1_x_TP53_mutation_50_percent_vaf': True, '1_x_TP53_mutation_10_percent_vaf': True}",
        "TP53 conditions: 2 mutations: True, with del17p: True, with LOH: True, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_TP53",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "edge_cases",
      "timestamp": "2025-06-06T19:49:19.480875"
    },
    {
      "test_id": "test_000140",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "ASXL1": true
        },
        "MDS_related_cytogenetics": {
          "Complex_karyotype": true
        },
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_50_percent_vaf": true
        },
        "qualifiers": {},
        "scenario_name": "elderly_mds_with_tp53",
        "scenario_description": "Elderly patient with MDS and TP53 mutation - classic high-risk scenario",
        "blasts_percentage": 12,
        "age": 75
      },
      "who_classification": "MDS with biallelic TP53 inactivation (WHO 2022)",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 12",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 12",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_category": "MDS_TP53",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "realistic_clinical_scenarios",
      "timestamp": "2025-06-06T19:49:19.480908"
    },
    {
      "test_id": "test_000141",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "scenario_name": "young_adult_npm1_aml",
        "scenario_description": "Young adult with NPM1+ AML - good prognosis group",
        "blasts_percentage": 85,
        "age": 28
      },
      "who_classification": "AML with NPM1 mutation (WHO 2022)",
      "icc_classification": "AML with mutated NPM1 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 85",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with NPM1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 85",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 => AML with mutated NPM1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated NPM1 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "realistic_clinical_scenarios",
      "timestamp": "2025-06-06T19:49:19.480924"
    },
    {
      "test_id": "test_000142",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true,
          "RUNX1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "previous_myeloid_malignancy": "Previous MDS"
        },
        "scenario_name": "aml_with_antecedent_mds",
        "scenario_description": "AML evolving from prior MDS - therapy-related scenario",
        "blasts_percentage": 35
      },
      "who_classification": "AML, myelodysplasia related (WHO 2022)",
      "icc_classification": "AML with myelodysplasia related gene mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 35",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "MDS-related mutation(s): SF3B1, RUNX1 => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 35",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "realistic_clinical_scenarios",
      "timestamp": "2025-06-06T19:49:19.480945"
    },
    {
      "test_id": "test_000143",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {
          "RUNX1::RUNX1T1": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "scenario_name": "core_binding_factor_aml",
        "scenario_description": "Core-binding factor AML with good prognosis",
        "blasts_percentage": 45
      },
      "who_classification": "AML with RUNX1::RUNX1T1 fusion (WHO 2022)",
      "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 45",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: RUNX1::RUNX1T1",
        "RUNX1::RUNX1T1 => AML with RUNX1::RUNX1T1 fusion",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with RUNX1::RUNX1T1 fusion (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 45",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => RUNX1::RUNX1T1",
        "RUNX1::RUNX1T1 => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with RUNX1::RUNX1T1 fusion",
        "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "realistic_clinical_scenarios",
      "timestamp": "2025-06-06T19:49:19.480963"
    },
    {
      "test_id": "test_000144",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_del_17p": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
        },
        "scenario_name": "therapy_related_aml_tp53",
        "scenario_description": "Therapy-related AML with TP53 mutation - poor prognosis",
        "blasts_percentage": 65
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy (WHO 2022)",
      "icc_classification": "AML with mutated TP53, therapy related (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 65",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
        "Final classification => Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 65",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts >=20 => remain AML",
        "Detected ICC therapy => therapy related: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => AML with mutated TP53, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
        "icc_classification": "AML with mutated TP53, therapy related",
        "who_category": "AML_THERAPY_RELATED",
        "icc_category": "AML_THERAPY_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "realistic_clinical_scenarios",
      "timestamp": "2025-06-06T19:49:19.480999"
    },
    {
      "test_id": "test_000145",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "scenario_name": "mds_sf3b1_ring_sideroblasts",
        "scenario_description": "MDS with SF3B1 mutation and ring sideroblasts",
        "blasts_percentage": 3,
        "number_of_dysplastic_lineages": 1
      },
      "who_classification": "MDS with low blasts and SF3B1 (WHO 2022)",
      "icc_classification": "MDS with mutated SF3B1 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 3",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 3, fibrotic: False",
        "SF3B1 mutation detected => MDS with low blasts and SF3B1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with low blasts and SF3B1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 3",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 3",
        "SF3B1 mutation detected => MDS with mutated SF3B1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with mutated SF3B1 (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with low blasts and SF3B1",
        "icc_classification": "MDS with mutated SF3B1",
        "who_category": "MDS_SF3B1",
        "icc_category": "MDS_SF3B1",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "realistic_clinical_scenarios",
      "timestamp": "2025-06-06T19:49:19.481021"
    },
    {
      "test_id": "test_000146",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "ASXL1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "scenario_name": "hypoplastic_mds",
        "scenario_description": "Hypoplastic MDS - can mimic aplastic anemia",
        "blasts_percentage": 8,
        "hypoplasia": true,
        "number_of_dysplastic_lineages": 2
      },
      "who_classification": "MDS with increased blasts 1 (WHO 2022)",
      "icc_classification": "MDS with excess blasts (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 8, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 8",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "realistic_clinical_scenarios",
      "timestamp": "2025-06-06T19:49:19.481041"
    },
    {
      "test_id": "test_000147",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "del_5q": true
        },
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "scenario_name": "fibrotic_mds",
        "scenario_description": "Fibrotic MDS - difficult to aspirate marrow",
        "blasts_percentage": 15,
        "fibrotic": true
      },
      "who_classification": "MDS, fibrotic (WHO 2022)",
      "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: True",
        "10-19% blasts => MDS with increased blasts 2",
        "Blasts 5-19% with fibrotic marrow => MDS, fibrotic",
        "Current classification: MDS, fibrotic",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, fibrotic (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS, fibrotic",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "diagnostic_uncertainty",
        "significance": "high"
      },
      "test_focus": "realistic_clinical_scenarios",
      "timestamp": "2025-06-06T19:49:19.481075"
    },
    {
      "test_id": "test_000148",
      "input_data": {
        "blasts_percentage": 25,
        "age": 12,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA": true,
          "bZIP": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "age_group": "pediatric",
        "genetic_context": "cebpa_bzip"
      },
      "who_classification": "AML with CEBPA mutation (WHO 2022)",
      "icc_classification": "AML with in-frame bZIP mutated CEBPA (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: CEBPA, bZIP",
        "CEBPA with blasts >=20 => AML with CEBPA mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with CEBPA mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => CEBPA, bZIP",
        "bZIP => AML with in-frame bZIP mutated CEBPA",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with in-frame bZIP mutated CEBPA (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with CEBPA mutation",
        "icc_classification": "AML with in-frame bZIP mutated CEBPA",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "age_dependent_differences",
      "timestamp": "2025-06-06T19:49:19.481098"
    },
    {
      "test_id": "test_000149",
      "input_data": {
        "blasts_percentage": 25,
        "age": 12,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true,
          "FLT3_ITD": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "age_group": "pediatric",
        "genetic_context": "npm1_flt3"
      },
      "who_classification": "AML with NPM1 mutation (WHO 2022)",
      "icc_classification": "AML with mutated NPM1 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1, FLT3_ITD",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with NPM1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1, FLT3_ITD",
        "NPM1 => AML with mutated NPM1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated NPM1 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "age_dependent_differences",
      "timestamp": "2025-06-06T19:49:19.481114"
    },
    {
      "test_id": "test_000150",
      "input_data": {
        "blasts_percentage": 25,
        "age": 12,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "predisposing_germline_variant": "germline RUNX1 mutation"
        },
        "age_group": "pediatric",
        "genetic_context": "runx1_germline"
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with germline RUNX1 mutation (WHO 2022)",
      "icc_classification": "AML, NOS, in the setting of germline RUNX1 mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "Detected germline predisposition => associated with germline RUNX1 mutation",
        "Classification with qualifiers => Acute myeloid leukaemia, unknown differentiation, associated with germline RUNX1 mutation",
        "Final classification => Acute myeloid leukaemia, unknown differentiation, associated with germline RUNX1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "Qualifier => in the setting of germline RUNX1 mutation",
        "Qualifiers appended => AML, NOS, in the setting of germline RUNX1 mutation (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with germline RUNX1 mutation",
        "icc_classification": "AML, NOS, in the setting of germline RUNX1 mutation",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_GENETIC",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_category_difference",
        "significance": "high"
      },
      "test_focus": "age_dependent_differences",
      "timestamp": "2025-06-06T19:49:19.481155"
    },
    {
      "test_id": "test_000151",
      "input_data": {
        "blasts_percentage": 25,
        "age": 12,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "predisposing_germline_variant": "germline DDX41 mutation"
        },
        "age_group": "pediatric",
        "genetic_context": "ddx41_germline"
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with germline DDX41 mutation (WHO 2022)",
      "icc_classification": "AML, NOS, in the setting of germline DDX41 mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "Detected germline predisposition => associated with germline DDX41 mutation",
        "Classification with qualifiers => Acute myeloid leukaemia, unknown differentiation, associated with germline DDX41 mutation",
        "Final classification => Acute myeloid leukaemia, unknown differentiation, associated with germline DDX41 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "Qualifier => in the setting of germline DDX41 mutation",
        "Qualifiers appended => AML, NOS, in the setting of germline DDX41 mutation (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with germline DDX41 mutation",
        "icc_classification": "AML, NOS, in the setting of germline DDX41 mutation",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "diagnostic_uncertainty",
        "significance": "high"
      },
      "test_focus": "age_dependent_differences",
      "timestamp": "2025-06-06T19:49:19.481208"
    },
    {
      "test_id": "test_000152",
      "input_data": {
        "blasts_percentage": 20,
        "age": 25,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA": true,
          "bZIP": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "age_group": "young_adult",
        "genetic_context": "cebpa_bzip"
      },
      "who_classification": "AML with CEBPA mutation (WHO 2022)",
      "icc_classification": "AML with in-frame bZIP mutated CEBPA (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: CEBPA, bZIP",
        "CEBPA with blasts >=20 => AML with CEBPA mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with CEBPA mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => CEBPA, bZIP",
        "bZIP => AML with in-frame bZIP mutated CEBPA",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with in-frame bZIP mutated CEBPA (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with CEBPA mutation",
        "icc_classification": "AML with in-frame bZIP mutated CEBPA",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "age_dependent_differences",
      "timestamp": "2025-06-06T19:49:19.481229"
    },
    {
      "test_id": "test_000153",
      "input_data": {
        "blasts_percentage": 20,
        "age": 25,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true,
          "FLT3_ITD": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "age_group": "young_adult",
        "genetic_context": "npm1_flt3"
      },
      "who_classification": "AML with NPM1 mutation (WHO 2022)",
      "icc_classification": "AML with mutated NPM1 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1, FLT3_ITD",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with NPM1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1, FLT3_ITD",
        "NPM1 => AML with mutated NPM1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated NPM1 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "age_dependent_differences",
      "timestamp": "2025-06-06T19:49:19.481246"
    },
    {
      "test_id": "test_000154",
      "input_data": {
        "blasts_percentage": 20,
        "age": 25,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "predisposing_germline_variant": "germline RUNX1 mutation"
        },
        "age_group": "young_adult",
        "genetic_context": "runx1_germline"
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with germline RUNX1 mutation (WHO 2022)",
      "icc_classification": "AML, NOS, in the setting of germline RUNX1 mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "Detected germline predisposition => associated with germline RUNX1 mutation",
        "Classification with qualifiers => Acute myeloid leukaemia, unknown differentiation, associated with germline RUNX1 mutation",
        "Final classification => Acute myeloid leukaemia, unknown differentiation, associated with germline RUNX1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "Qualifier => in the setting of germline RUNX1 mutation",
        "Qualifiers appended => AML, NOS, in the setting of germline RUNX1 mutation (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with germline RUNX1 mutation",
        "icc_classification": "AML, NOS, in the setting of germline RUNX1 mutation",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_GENETIC",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_category_difference",
        "significance": "high"
      },
      "test_focus": "age_dependent_differences",
      "timestamp": "2025-06-06T19:49:19.481288"
    },
    {
      "test_id": "test_000155",
      "input_data": {
        "blasts_percentage": 20,
        "age": 25,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "predisposing_germline_variant": "germline DDX41 mutation"
        },
        "age_group": "young_adult",
        "genetic_context": "ddx41_germline"
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with germline DDX41 mutation (WHO 2022)",
      "icc_classification": "AML, NOS, in the setting of germline DDX41 mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "Detected germline predisposition => associated with germline DDX41 mutation",
        "Classification with qualifiers => Acute myeloid leukaemia, unknown differentiation, associated with germline DDX41 mutation",
        "Final classification => Acute myeloid leukaemia, unknown differentiation, associated with germline DDX41 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "Qualifier => in the setting of germline DDX41 mutation",
        "Qualifiers appended => AML, NOS, in the setting of germline DDX41 mutation (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with germline DDX41 mutation",
        "icc_classification": "AML, NOS, in the setting of germline DDX41 mutation",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "diagnostic_uncertainty",
        "significance": "high"
      },
      "test_focus": "age_dependent_differences",
      "timestamp": "2025-06-06T19:49:19.481333"
    },
    {
      "test_id": "test_000156",
      "input_data": {
        "blasts_percentage": 18,
        "age": 55,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA": true,
          "bZIP": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "age_group": "middle_aged",
        "genetic_context": "cebpa_bzip"
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "AML with in-frame bZIP mutated CEBPA (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: CEBPA, bZIP",
        "CEBPA found but blasts <20 => not AML by this route",
        "bZIP found but blasts <20 => not AML by this route",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 18, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => CEBPA, bZIP",
        "bZIP => AML with in-frame bZIP mutated CEBPA",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with in-frame bZIP mutated CEBPA (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "AML with in-frame bZIP mutated CEBPA",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_GENETIC",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_category_difference",
        "significance": "high"
      },
      "test_focus": "age_dependent_differences",
      "timestamp": "2025-06-06T19:49:19.481368"
    },
    {
      "test_id": "test_000157",
      "input_data": {
        "blasts_percentage": 18,
        "age": 55,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true,
          "FLT3_ITD": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "age_group": "middle_aged",
        "genetic_context": "npm1_flt3"
      },
      "who_classification": "AML with NPM1 mutation (WHO 2022)",
      "icc_classification": "AML with mutated NPM1 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1, FLT3_ITD",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with NPM1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1, FLT3_ITD",
        "NPM1 => AML with mutated NPM1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated NPM1 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "age_dependent_differences",
      "timestamp": "2025-06-06T19:49:19.481385"
    },
    {
      "test_id": "test_000158",
      "input_data": {
        "blasts_percentage": 18,
        "age": 55,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "predisposing_germline_variant": "germline RUNX1 mutation"
        },
        "age_group": "middle_aged",
        "genetic_context": "runx1_germline"
      },
      "who_classification": "MDS with increased blasts 2, associated with germline RUNX1 mutation (WHO 2022)",
      "icc_classification": "MDS/AML, NOS, in the setting of germline RUNX1 mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "Detected germline predisposition => associated with germline RUNX1 mutation",
        "Classification with qualifiers => Not AML, consider MDS classification, associated with germline RUNX1 mutation",
        "Final classification => Not AML, consider MDS classification, associated with germline RUNX1 mutation",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 18, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "Detected germline predisposition => associated with germline RUNX1 mutation",
        "Classification with qualifiers: MDS with increased blasts 2, associated with germline RUNX1 mutation",
        "Final classification => MDS with increased blasts 2, associated with germline RUNX1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "Qualifier => in the setting of germline RUNX1 mutation",
        "Qualifiers appended => MDS/AML, NOS, in the setting of germline RUNX1 mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2, associated with germline RUNX1 mutation",
        "icc_classification": "MDS/AML, NOS, in the setting of germline RUNX1 mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_GENETIC",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_category_difference",
        "significance": "high"
      },
      "test_focus": "age_dependent_differences",
      "timestamp": "2025-06-06T19:49:19.481428"
    },
    {
      "test_id": "test_000159",
      "input_data": {
        "blasts_percentage": 18,
        "age": 55,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "predisposing_germline_variant": "germline DDX41 mutation"
        },
        "age_group": "middle_aged",
        "genetic_context": "ddx41_germline"
      },
      "who_classification": "MDS with increased blasts 2, associated with germline DDX41 mutation (WHO 2022)",
      "icc_classification": "MDS/AML, NOS, in the setting of germline DDX41 mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "Detected germline predisposition => associated with germline DDX41 mutation",
        "Classification with qualifiers => Not AML, consider MDS classification, associated with germline DDX41 mutation",
        "Final classification => Not AML, consider MDS classification, associated with germline DDX41 mutation",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 18, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "Detected germline predisposition => associated with germline DDX41 mutation",
        "Classification with qualifiers: MDS with increased blasts 2, associated with germline DDX41 mutation",
        "Final classification => MDS with increased blasts 2, associated with germline DDX41 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "Qualifier => in the setting of germline DDX41 mutation",
        "Qualifiers appended => MDS/AML, NOS, in the setting of germline DDX41 mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2, associated with germline DDX41 mutation",
        "icc_classification": "MDS/AML, NOS, in the setting of germline DDX41 mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "mds_aml_hybrid_difference",
        "significance": "medium"
      },
      "test_focus": "age_dependent_differences",
      "timestamp": "2025-06-06T19:49:19.481478"
    },
    {
      "test_id": "test_000160",
      "input_data": {
        "blasts_percentage": 15,
        "age": 78,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA": true,
          "bZIP": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "age_group": "elderly",
        "genetic_context": "cebpa_bzip"
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "AML with in-frame bZIP mutated CEBPA (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: CEBPA, bZIP",
        "CEBPA found but blasts <20 => not AML by this route",
        "bZIP found but blasts <20 => not AML by this route",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => CEBPA, bZIP",
        "bZIP => AML with in-frame bZIP mutated CEBPA",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with in-frame bZIP mutated CEBPA (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "AML with in-frame bZIP mutated CEBPA",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_GENETIC",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_category_difference",
        "significance": "high"
      },
      "test_focus": "age_dependent_differences",
      "timestamp": "2025-06-06T19:49:19.481511"
    },
    {
      "test_id": "test_000161",
      "input_data": {
        "blasts_percentage": 15,
        "age": 78,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true,
          "FLT3_ITD": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "age_group": "elderly",
        "genetic_context": "npm1_flt3"
      },
      "who_classification": "AML with NPM1 mutation (WHO 2022)",
      "icc_classification": "AML with mutated NPM1 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1, FLT3_ITD",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with NPM1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1, FLT3_ITD",
        "NPM1 => AML with mutated NPM1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated NPM1 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "age_dependent_differences",
      "timestamp": "2025-06-06T19:49:19.481529"
    },
    {
      "test_id": "test_000162",
      "input_data": {
        "blasts_percentage": 15,
        "age": 78,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "predisposing_germline_variant": "germline RUNX1 mutation"
        },
        "age_group": "elderly",
        "genetic_context": "runx1_germline"
      },
      "who_classification": "MDS with increased blasts 2, associated with germline RUNX1 mutation (WHO 2022)",
      "icc_classification": "MDS/AML, NOS, in the setting of germline RUNX1 mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "Detected germline predisposition => associated with germline RUNX1 mutation",
        "Classification with qualifiers => Not AML, consider MDS classification, associated with germline RUNX1 mutation",
        "Final classification => Not AML, consider MDS classification, associated with germline RUNX1 mutation",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "Detected germline predisposition => associated with germline RUNX1 mutation",
        "Classification with qualifiers: MDS with increased blasts 2, associated with germline RUNX1 mutation",
        "Final classification => MDS with increased blasts 2, associated with germline RUNX1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "Qualifier => in the setting of germline RUNX1 mutation",
        "Qualifiers appended => MDS/AML, NOS, in the setting of germline RUNX1 mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2, associated with germline RUNX1 mutation",
        "icc_classification": "MDS/AML, NOS, in the setting of germline RUNX1 mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_GENETIC",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_category_difference",
        "significance": "high"
      },
      "test_focus": "age_dependent_differences",
      "timestamp": "2025-06-06T19:49:19.481568"
    },
    {
      "test_id": "test_000163",
      "input_data": {
        "blasts_percentage": 15,
        "age": 78,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "predisposing_germline_variant": "germline DDX41 mutation"
        },
        "age_group": "elderly",
        "genetic_context": "ddx41_germline"
      },
      "who_classification": "MDS with increased blasts 2, associated with germline DDX41 mutation (WHO 2022)",
      "icc_classification": "MDS/AML, NOS, in the setting of germline DDX41 mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "Detected germline predisposition => associated with germline DDX41 mutation",
        "Classification with qualifiers => Not AML, consider MDS classification, associated with germline DDX41 mutation",
        "Final classification => Not AML, consider MDS classification, associated with germline DDX41 mutation",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "Detected germline predisposition => associated with germline DDX41 mutation",
        "Classification with qualifiers: MDS with increased blasts 2, associated with germline DDX41 mutation",
        "Final classification => MDS with increased blasts 2, associated with germline DDX41 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "Qualifier => in the setting of germline DDX41 mutation",
        "Qualifiers appended => MDS/AML, NOS, in the setting of germline DDX41 mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2, associated with germline DDX41 mutation",
        "icc_classification": "MDS/AML, NOS, in the setting of germline DDX41 mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "mds_aml_hybrid_difference",
        "significance": "medium"
      },
      "test_focus": "age_dependent_differences",
      "timestamp": "2025-06-06T19:49:19.481612"
    },
    {
      "test_id": "test_000164",
      "input_data": {
        "blasts_percentage": 22,
        "MDS_related_cytogenetics": {
          "Complex_karyotype": true,
          "del_17p": true
        },
        "MDS_related_mutation": {},
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_del_17p": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "qualifiers": {},
        "scenario_name": "complex_karyotype_tp53",
        "scenario_description": "Complex karyotype with TP53 mutation"
      },
      "who_classification": "AML, myelodysplasia related (WHO 2022)",
      "icc_classification": "AML with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 22",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "MDS-related cytogenetic(s): Complex_karyotype, del_17p => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 22",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "diagnostic_uncertainty",
        "significance": "high"
      },
      "test_focus": "complex_cytogenetics",
      "timestamp": "2025-06-06T19:49:19.481647"
    },
    {
      "test_id": "test_000165",
      "input_data": {
        "blasts_percentage": 18,
        "MDS_related_cytogenetics": {
          "del_5q": true
        },
        "MDS_related_mutation": {
          "ASXL1": true
        },
        "Biallelic_TP53_mutation": {},
        "AML_defining_recurrent_genetic_abnormalities": {},
        "qualifiers": {},
        "scenario_name": "del5q_syndrome_progression",
        "scenario_description": "del(5q) syndrome with blast progression"
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 18, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "complex_cytogenetics",
      "timestamp": "2025-06-06T19:49:19.481681"
    },
    {
      "test_id": "test_000166",
      "input_data": {
        "blasts_percentage": 25,
        "MDS_related_cytogenetics": {
          "-7": true
        },
        "MDS_related_mutation": {},
        "Biallelic_TP53_mutation": {},
        "AML_defining_recurrent_genetic_abnormalities": {},
        "qualifiers": {},
        "scenario_name": "monosomy7_childhood",
        "scenario_description": "Monosomy 7 in young patient",
        "age": 8
      },
      "who_classification": "AML, myelodysplasia related (WHO 2022)",
      "icc_classification": "AML with myelodysplasia related cytogenetic abnormality (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "MDS-related cytogenetic(s): -7 => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "complex_cytogenetics",
      "timestamp": "2025-06-06T19:49:19.481705"
    },
    {
      "test_id": "test_000167",
      "input_data": {
        "blasts_percentage": 45,
        "MDS_related_cytogenetics": {
          "inv3_t33": true
        },
        "MDS_related_mutation": {
          "EVI1": true
        },
        "Biallelic_TP53_mutation": {},
        "AML_defining_recurrent_genetic_abnormalities": {},
        "qualifiers": {},
        "scenario_name": "inv3_evi1_aml",
        "scenario_description": "inv(3) with EVI1 rearrangement"
      },
      "who_classification": "AML, myelodysplasia related (WHO 2022)",
      "icc_classification": "AML with myelodysplasia related gene mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 45",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "MDS-related mutation(s): EVI1 => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 45",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "complex_cytogenetics",
      "timestamp": "2025-06-06T19:49:19.481727"
    },
    {
      "test_id": "test_000168",
      "input_data": {
        "blasts_percentage": 8,
        "MDS_related_cytogenetics": {
          "del_7q": true
        },
        "MDS_related_mutation": {
          "RUNX1": true
        },
        "Biallelic_TP53_mutation": {},
        "AML_defining_recurrent_genetic_abnormalities": {},
        "qualifiers": {},
        "scenario_name": "del7q_mds",
        "scenario_description": "del(7q) in MDS"
      },
      "who_classification": "MDS with increased blasts 1 (WHO 2022)",
      "icc_classification": "MDS with excess blasts (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 8, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 8",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "complex_cytogenetics",
      "timestamp": "2025-06-06T19:49:19.481748"
    },
    {
      "test_id": "test_000169",
      "input_data": {
        "blasts_percentage": 28,
        "MDS_related_cytogenetics": {},
        "MDS_related_mutation": {
          "DNMT3A": true,
          "TET2": true,
          "ASXL1": true
        },
        "Biallelic_TP53_mutation": {},
        "AML_defining_recurrent_genetic_abnormalities": {},
        "qualifiers": {},
        "scenario_name": "normal_karyotype_multiple_mutations",
        "scenario_description": "Normal karyotype with multiple mutations"
      },
      "who_classification": "AML, myelodysplasia related (WHO 2022)",
      "icc_classification": "AML with myelodysplasia related gene mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 28",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "MDS-related mutation(s): DNMT3A, TET2, ASXL1 => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 28",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "complex_cytogenetics",
      "timestamp": "2025-06-06T19:49:19.481768"
    },
    {
      "test_id": "test_000170",
      "input_data": {
        "blasts_percentage": 75,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true,
          "FLT3_ITD": true
        },
        "MDS_related_mutation": {
          "DNMT3A": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "pattern_name": "dnmt3a_npm1_flt3",
        "pattern_description": "DNMT3A + NPM1 + FLT3-ITD triple mutation"
      },
      "who_classification": "AML with NPM1 mutation (WHO 2022)",
      "icc_classification": "AML with mutated NPM1 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 75",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1, FLT3_ITD",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with NPM1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 75",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1, FLT3_ITD",
        "NPM1 => AML with mutated NPM1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated NPM1 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "comutation_patterns",
      "timestamp": "2025-06-06T19:49:19.481784"
    },
    {
      "test_id": "test_000171",
      "input_data": {
        "blasts_percentage": 5,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "TET2": true,
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "pattern_name": "tet2_sf3b1_mds",
        "pattern_description": "TET2 + SF3B1 in MDS with ring sideroblasts"
      },
      "who_classification": "MDS with increased blasts 1 (WHO 2022)",
      "icc_classification": "MDS with excess blasts (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 5, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 5",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "comutation_patterns",
      "timestamp": "2025-06-06T19:49:19.481804"
    },
    {
      "test_id": "test_000172",
      "input_data": {
        "blasts_percentage": 16,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "ASXL1": true,
          "RUNX1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "pattern_name": "asxl1_runx1_poor_risk",
        "pattern_description": "ASXL1 + RUNX1 mutations - poor risk combination"
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 16",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 16, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 16",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "comutation_patterns",
      "timestamp": "2025-06-06T19:49:19.481836"
    },
    {
      "test_id": "test_000173",
      "input_data": {
        "blasts_percentage": 35,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "Complex_karyotype": true
        },
        "Biallelic_TP53_mutation": {
          "2_x_TP53_mutations": true
        },
        "qualifiers": {},
        "pattern_name": "tp53_complex_karyotype",
        "pattern_description": "TP53 mutation with complex karyotype"
      },
      "who_classification": "AML, myelodysplasia related (WHO 2022)",
      "icc_classification": "AML with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 35",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "MDS-related cytogenetic(s): Complex_karyotype => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 35",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "diagnostic_uncertainty",
        "significance": "high"
      },
      "test_focus": "comutation_patterns",
      "timestamp": "2025-06-06T19:49:19.481866"
    },
    {
      "test_id": "test_000174",
      "input_data": {
        "blasts_percentage": 12,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SRSF2": true,
          "TET2": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "pattern_name": "srsf2_tet2_cmml_like",
        "pattern_description": "SRSF2 + TET2 mutations - CMML-like pattern"
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 12",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 12, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 12",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "comutation_patterns",
      "timestamp": "2025-06-06T19:49:19.481898"
    },
    {
      "test_id": "test_000175",
      "input_data": {
        "blasts_percentage": 9,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "U2AF1": true,
          "DNMT3A": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
        },
        "pattern_name": "u2af1_dnmt3a_secondary",
        "pattern_description": "U2AF1 + DNMT3A in therapy-related MDS"
      },
      "who_classification": "MDS with increased blasts 1, previous cytotoxic therapy (WHO 2022)",
      "icc_classification": "MDS with excess blasts, therapy related (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => Not AML, consider MDS classification, previous cytotoxic therapy",
        "Final classification => Not AML, consider MDS classification, previous cytotoxic therapy",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 9, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers: MDS with increased blasts 1, previous cytotoxic therapy",
        "Final classification => MDS with increased blasts 1, previous cytotoxic therapy (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "Detected ICC therapy => therapy related: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 9",
        "5-9% blasts => MDS with excess blasts",
        "Detected ICC therapy => therapy related: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => MDS with excess blasts, therapy related",
        "Final classification => MDS with excess blasts, therapy related (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1, previous cytotoxic therapy",
        "icc_classification": "MDS with excess blasts, therapy related",
        "who_category": "AML_THERAPY_RELATED",
        "icc_category": "AML_THERAPY_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "comutation_patterns",
      "timestamp": "2025-06-06T19:49:19.481932"
    },
    {
      "test_id": "test_000176",
      "input_data": {
        "blasts_percentage": 14,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "EZH2": true,
          "ASXL1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "pattern_name": "ezh2_asxl1_high_risk",
        "pattern_description": "EZH2 + ASXL1 high-risk combination"
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 14",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 14, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 14",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "comutation_patterns",
      "timestamp": "2025-06-06T19:49:19.481964"
    },
    {
      "test_id": "test_000177",
      "input_data": {
        "blasts_percentage": 25,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true,
          "NRAS": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "Previous MDS"
        },
        "scenario_name": "mds_to_aml_progression",
        "scenario_description": "MDS progression to AML with acquired mutations"
      },
      "who_classification": "AML, myelodysplasia related (WHO 2022)",
      "icc_classification": "AML with myelodysplasia related gene mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "MDS-related mutation(s): SF3B1, NRAS => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "therapy_evolution",
      "timestamp": "2025-06-06T19:49:19.481983"
    },
    {
      "test_id": "test_000178",
      "input_data": {
        "blasts_percentage": 45,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "Complex_karyotype": true
        },
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_50_percent_vaf": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
        },
        "scenario_name": "post_chemo_aml_tp53",
        "scenario_description": "Therapy-related AML with TP53 after chemotherapy"
      },
      "who_classification": "AML, myelodysplasia related, previous cytotoxic therapy (WHO 2022)",
      "icc_classification": "AML with myelodysplasia related cytogenetic abnormality, therapy related (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 45",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "MDS-related cytogenetic(s): Complex_karyotype => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => AML, myelodysplasia related, previous cytotoxic therapy",
        "Final classification => AML, myelodysplasia related, previous cytotoxic therapy (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 45",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
        "Blasts >=20 => remain AML",
        "Detected ICC therapy => therapy related: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => AML with myelodysplasia related cytogenetic abnormality, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related, previous cytotoxic therapy",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality, therapy related",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "therapy_evolution",
      "timestamp": "2025-06-06T19:49:19.482025"
    },
    {
      "test_id": "test_000179",
      "input_data": {
        "blasts_percentage": 60,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "NPM1": true,
          "TP53": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
        },
        "scenario_name": "relapsed_aml_new_mutations",
        "scenario_description": "Relapsed AML with additional mutations"
      },
      "who_classification": "AML, myelodysplasia related, previous cytotoxic therapy (WHO 2022)",
      "icc_classification": "AML with myelodysplasia related gene mutation, therapy related (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 60",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "MDS-related mutation(s): NPM1, TP53 => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => AML, myelodysplasia related, previous cytotoxic therapy",
        "Final classification => AML, myelodysplasia related, previous cytotoxic therapy (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 60",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts >=20 => remain AML",
        "Detected ICC therapy => therapy related: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => AML with myelodysplasia related gene mutation, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related, previous cytotoxic therapy",
        "icc_classification": "AML with myelodysplasia related gene mutation, therapy related",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "therapy_evolution",
      "timestamp": "2025-06-06T19:49:19.482064"
    },
    {
      "test_id": "test_000180",
      "input_data": {
        "blasts_percentage": 12,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "del_5q": true,
          "Complex_karyotype": true
        },
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "Ionising radiation"
        },
        "scenario_name": "post_radiation_mds",
        "scenario_description": "Radiation-induced MDS with del(5q)"
      },
      "who_classification": "MDS with increased blasts 2, previous cytotoxic therapy (WHO 2022)",
      "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality, therapy related (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 12",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "Detected WHO therapy => previous cytotoxic therapy: Ionising radiation",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => Not AML, consider MDS classification, previous cytotoxic therapy",
        "Final classification => Not AML, consider MDS classification, previous cytotoxic therapy",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 12, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "Detected WHO therapy => previous cytotoxic therapy: Ionising radiation",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers: MDS with increased blasts 2, previous cytotoxic therapy",
        "Final classification => MDS with increased blasts 2, previous cytotoxic therapy (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 12",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
        "Detected ICC therapy => therapy related: Ionising radiation",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => MDS/AML with myelodysplasia related cytogenetic abnormality, therapy related (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2, previous cytotoxic therapy",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality, therapy related",
        "who_category": "AML_THERAPY_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "therapy_evolution",
      "timestamp": "2025-06-06T19:49:19.482106"
    },
    {
      "test_id": "test_000181",
      "input_data": {
        "blasts_percentage": 18,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "ASXL1": true,
          "TET2": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "Immune interventions"
        },
        "scenario_name": "immune_therapy_related",
        "scenario_description": "Post-immunotherapy myeloid neoplasm"
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation, therapy related (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 18, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "Detected ICC therapy => therapy related: Immune interventions",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => MDS/AML with myelodysplasia related gene mutation, therapy related (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation, therapy related",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "therapy_evolution",
      "timestamp": "2025-06-06T19:49:19.482142"
    },
    {
      "test_id": "test_000182",
      "input_data": {
        "test_name": "blast_15_with_cebpa_bzip",
        "description": "15% blasts with CEBPA bZIP mutation - ICC may call AML, WHO may call MDS",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 15,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA_bZIP": true
        },
        "dysplastic_lineages": 1,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: CEBPA_bZIP",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => CEBPA_bZIP",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "mds_aml_hybrid_difference",
        "significance": "medium"
      },
      "test_focus": "aml_vs_mds_borderline",
      "timestamp": "2025-06-06T19:49:19.482179"
    },
    {
      "test_id": "test_000183",
      "input_data": {
        "test_name": "blast_12_with_npm1",
        "description": "12% blasts with NPM1 mutation - borderline case",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 12,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1_mutation": true
        },
        "dysplastic_lineages": 2,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 12",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1_mutation",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 12, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 12",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1_mutation",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "mds_aml_hybrid_difference",
        "significance": "medium"
      },
      "test_focus": "aml_vs_mds_borderline",
      "timestamp": "2025-06-06T19:49:19.482210"
    },
    {
      "test_id": "test_000184",
      "input_data": {
        "test_name": "blast_18_with_runx1_runx1t1",
        "description": "18% blasts with RUNX1-RUNX1T1 fusion",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 18,
        "AML_defining_recurrent_genetic_abnormalities": {
          "RUNX1_RUNX1T1": true
        },
        "dysplastic_lineages": 1,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: RUNX1_RUNX1T1",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 18, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => RUNX1_RUNX1T1",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "mds_aml_hybrid_difference",
        "significance": "medium"
      },
      "test_focus": "aml_vs_mds_borderline",
      "timestamp": "2025-06-06T19:49:19.482240"
    },
    {
      "test_id": "test_000185",
      "input_data": {
        "test_name": "blast_16_with_inv16",
        "description": "16% blasts with inv(16) - core binding factor",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 16,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CBFB_MYH11": true
        },
        "dysplastic_lineages": 0,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 16",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: CBFB_MYH11",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 16, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 16",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => CBFB_MYH11",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "mds_aml_hybrid_difference",
        "significance": "medium"
      },
      "test_focus": "aml_vs_mds_borderline",
      "timestamp": "2025-06-06T19:49:19.482272"
    },
    {
      "test_id": "test_000186",
      "input_data": {
        "test_name": "blast_19_with_sf3b1_asxl1",
        "description": "19% blasts with SF3B1 and ASXL1 mutations",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 19,
        "MDS_related_mutation": {
          "SF3B1": true,
          "ASXL1": true
        },
        "dysplastic_lineages": 3,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 19, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "aml_vs_mds_borderline",
      "timestamp": "2025-06-06T19:49:19.482307"
    },
    {
      "test_id": "test_000187",
      "input_data": {
        "test_name": "blast_21_with_tet2_dnmt3a",
        "description": "21% blasts with TET2 and DNMT3A mutations",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 21,
        "MDS_related_mutation": {
          "TET2": true,
          "DNMT3A": true
        },
        "dysplastic_lineages": 2,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "AML, myelodysplasia related (WHO 2022)",
      "icc_classification": "AML with myelodysplasia related gene mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 21",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "MDS-related mutation(s): TET2, DNMT3A => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 21",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "aml_vs_mds_borderline",
      "timestamp": "2025-06-06T19:49:19.482328"
    },
    {
      "test_id": "test_000188",
      "input_data": {
        "test_name": "blast_18_with_srsf2_u2af1",
        "description": "18% blasts with SRSF2 and U2AF1 mutations",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 18,
        "MDS_related_mutation": {
          "SRSF2": true,
          "U2AF1": true
        },
        "dysplastic_lineages": 2,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 18, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "aml_vs_mds_borderline",
      "timestamp": "2025-06-06T19:49:19.482359"
    },
    {
      "test_id": "test_000189",
      "input_data": {
        "test_name": "tr_blast_15_with_tp53",
        "description": "Therapy-related case with 15% blasts and TP53 mutation",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 15,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_50_percent_vaf": true
        },
        "therapy_qualifier": "Cytotoxic chemotherapy",
        "dysplastic_lineages": 2,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "MDS with biallelic TP53 inactivation (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "aml_vs_mds_borderline",
      "timestamp": "2025-06-06T19:49:19.482388"
    },
    {
      "test_id": "test_000190",
      "input_data": {
        "test_name": "tr_blast_22_complex_karyotype",
        "description": "Therapy-related case with 22% blasts and complex karyotype",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 22,
        "complex_karyotype": true,
        "therapy_qualifier": "Ionising radiation",
        "dysplastic_lineages": 3,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation (WHO 2022)",
      "icc_classification": "AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 22",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 22",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": true,
        "category_match": false,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "aml_vs_mds_borderline",
      "timestamp": "2025-06-06T19:49:19.482410"
    },
    {
      "test_id": "test_000191",
      "input_data": {
        "test_name": "erythroid_blast_18_dysplastic",
        "description": "18% blasts with erythroid predominance and dysplasia",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 18,
        "AML_differentiation": "M6",
        "dysplastic_lineages": 2,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "AML_differentiation: M6",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 18, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "mds_aml_hybrid_difference",
        "significance": "medium"
      },
      "test_focus": "aml_vs_mds_borderline",
      "timestamp": "2025-06-06T19:49:19.482439"
    },
    {
      "test_id": "test_000192",
      "input_data": {
        "test_name": "erythroid_blast_25_with_sf3b1",
        "description": "25% blasts with erythroid features and SF3B1 mutation",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 25,
        "AML_differentiation": "M6",
        "MDS_related_mutation": {
          "SF3B1": true
        },
        "dysplastic_lineages": 1,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "AML, myelodysplasia related (WHO 2022)",
      "icc_classification": "AML with myelodysplasia related gene mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "MDS-related mutation(s): SF3B1 => AML, myelodysplasia related",
        "AML_differentiation: M6",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "aml_vs_mds_borderline",
      "timestamp": "2025-06-06T19:49:19.482460"
    },
    {
      "test_id": "test_000193",
      "input_data": {
        "test_name": "blast_19_npm1_with_dysplasia",
        "description": "19% blasts with NPM1 mutation but significant dysplasia",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1_mutation": true
        },
        "MDS_related_mutation": {
          "DNMT3A": true,
          "TET2": true
        },
        "dysplastic_lineages": 3,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1_mutation",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 19, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1_mutation",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "aml_vs_mds_borderline",
      "timestamp": "2025-06-06T19:49:19.482496"
    },
    {
      "test_id": "test_000194",
      "input_data": {
        "test_name": "blast_17_flt3_with_mds_changes",
        "description": "17% blasts with FLT3-ITD and MDS-related changes",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 17,
        "AML_defining_recurrent_genetic_abnormalities": {
          "FLT3_ITD": true
        },
        "MDS_related_mutation": {
          "ASXL1": true,
          "SRSF2": true
        },
        "dysplastic_lineages": 2,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 17",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: FLT3_ITD",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 17, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 17",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => FLT3_ITD",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "aml_vs_mds_borderline",
      "timestamp": "2025-06-06T19:49:19.482534"
    },
    {
      "test_id": "test_000195",
      "input_data": {
        "test_name": "blast_21_cebpa_with_complex_karyotype",
        "description": "21% blasts with CEBPA mutation and complex karyotype",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 21,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA_bZIP": true
        },
        "complex_karyotype": true,
        "dysplastic_lineages": 2,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation (WHO 2022)",
      "icc_classification": "AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 21",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: CEBPA_bZIP",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 21",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => CEBPA_bZIP",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": true,
        "category_match": false,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "aml_vs_mds_borderline",
      "timestamp": "2025-06-06T19:49:19.482557"
    },
    {
      "test_id": "test_000196",
      "input_data": {
        "test_name": "previous_mds_blast_18",
        "description": "18% blasts in patient with previous MDS diagnosis",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 18,
        "MDS_related_mutation": {
          "TET2": true,
          "SF3B1": true
        },
        "previous_mds_mpn": "Previous MDS",
        "dysplastic_lineages": 2,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 18, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "aml_vs_mds_borderline",
      "timestamp": "2025-06-06T19:49:19.482591"
    },
    {
      "test_id": "test_000197",
      "input_data": {
        "test_name": "previous_mds_blast_22_with_new_mutation",
        "description": "22% blasts with previous MDS and new AML-defining mutation",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 22,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1_mutation": true
        },
        "MDS_related_mutation": {
          "TET2": true
        },
        "previous_mds_mpn": "Previous MDS",
        "dysplastic_lineages": 1,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "AML, myelodysplasia related (WHO 2022)",
      "icc_classification": "AML with myelodysplasia related gene mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 22",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1_mutation",
        "MDS-related mutation(s): TET2 => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 22",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1_mutation",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "aml_vs_mds_borderline",
      "timestamp": "2025-06-06T19:49:19.482615"
    },
    {
      "test_id": "test_000198",
      "input_data": {
        "test_name": "who_aml_icc_mds_blast_20_with_dysplasia",
        "description": "20% blasts with extensive dysplasia - WHO may favor AML, ICC may favor MDS",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 20,
        "dysplastic_lineages": 3,
        "MDS_related_mutation": {
          "ASXL1": true,
          "TET2": true,
          "SRSF2": true
        },
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "AML, myelodysplasia related (WHO 2022)",
      "icc_classification": "AML with myelodysplasia related gene mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "MDS-related mutation(s): ASXL1, TET2, SRSF2 => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "disease_type_disagreement",
      "timestamp": "2025-06-06T19:49:19.482694"
    },
    {
      "test_id": "test_000199",
      "input_data": {
        "test_name": "blast_20_with_ring_sideroblasts",
        "description": "20% blasts with >15% ring sideroblasts and SF3B1 mutation",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 20,
        "MDS_related_mutation": {
          "SF3B1": true
        },
        "dysplastic_lineages": 1,
        "bone_marrow_cellularity": "Hypercellular",
        "ring_sideroblasts_percent": 25
      },
      "who_classification": "AML, myelodysplasia related (WHO 2022)",
      "icc_classification": "AML with myelodysplasia related gene mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "MDS-related mutation(s): SF3B1 => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "disease_type_disagreement",
      "timestamp": "2025-06-06T19:49:19.482735"
    },
    {
      "test_id": "test_000200",
      "input_data": {
        "test_name": "who_mds_icc_aml_blast_15_cebpa",
        "description": "15% blasts with CEBPA bZIP - ICC may call AML, WHO may call MDS",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 15,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA_bZIP": true
        },
        "dysplastic_lineages": 1,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: CEBPA_bZIP",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => CEBPA_bZIP",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "mds_aml_hybrid_difference",
        "significance": "medium"
      },
      "test_focus": "disease_type_disagreement",
      "timestamp": "2025-06-06T19:49:19.482782"
    },
    {
      "test_id": "test_000201",
      "input_data": {
        "test_name": "blast_12_with_bcr_abl1",
        "description": "12% blasts with BCR::ABL1 fusion",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 12,
        "AML_defining_recurrent_genetic_abnormalities": {
          "BCR::ABL1": true
        },
        "dysplastic_lineages": 0,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 12",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: BCR::ABL1",
        "BCR::ABL1 found but blasts <20 => not AML by this route",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 12, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 12",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => BCR::ABL1",
        "BCR::ABL1 => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_GENETIC",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_category_difference",
        "significance": "high"
      },
      "test_focus": "disease_type_disagreement",
      "timestamp": "2025-06-06T19:49:19.482885"
    },
    {
      "test_id": "test_000202",
      "input_data": {
        "test_name": "blast_18_with_kmt2a_rearrangement",
        "description": "18% blasts with KMT2A rearrangement",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 18,
        "AML_defining_recurrent_genetic_abnormalities": {
          "KMT2A_rearranged": true
        },
        "dysplastic_lineages": 0,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: KMT2A_rearranged",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 18, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => KMT2A_rearranged",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "mds_aml_hybrid_difference",
        "significance": "medium"
      },
      "test_focus": "disease_type_disagreement",
      "timestamp": "2025-06-06T19:49:19.482938"
    },
    {
      "test_id": "test_000203",
      "input_data": {
        "test_name": "tr_blast_15_immune_intervention",
        "description": "15% blasts after immune intervention therapy",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 15,
        "therapy_qualifier": "Immune interventions (ICC)",
        "MDS_related_mutation": {
          "TP53": true
        },
        "dysplastic_lineages": 2,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "disease_type_disagreement",
      "timestamp": "2025-06-06T19:49:19.482980"
    },
    {
      "test_id": "test_000204",
      "input_data": {
        "test_name": "tr_blast_19_with_aml_mutation",
        "description": "19% blasts after chemotherapy with new AML-defining mutation",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 19,
        "therapy_qualifier": "Cytotoxic chemotherapy",
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1_mutation": true
        },
        "dysplastic_lineages": 1,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1_mutation",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 19, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1_mutation",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "mds_aml_hybrid_difference",
        "significance": "medium"
      },
      "test_focus": "disease_type_disagreement",
      "timestamp": "2025-06-06T19:49:19.483018"
    }
  ],
  "timestamp": "2025-06-06T19:49:19.491907",
  "total_tests": 204
}